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Introduction 
 
The aim of this work is to draw up a first draft of an assessment report of Hypericum 
perforatum L. with well-established use (based on article 10A of directive 2001/83/EC) 
and/or traditional use (based on article 16D(1) and article 16H of directive 2001/83/EC as 
amended by directive 2004/24/EC) for the Committee for Herbal Medicinal Products at the 
European Medicines Agency (EMEA), where Austria is the assigned rapporteur for this 
project. 
 
Background: 
With the publication of the directive 2004/24/EC traditional herbal medicinal products were 
defined as a new class of medicinal products. In order to facilitate the harmonisation process a 
new committee has been established at the EMEA, the Committee for Herbal Medicinal 
Products (HMPC). This committee should elaborate so called community monographs and 
community list entries for herbal preparations. These monographs should be relevant for the 
registration or authorisation of herbal medicinal products. The main content of such a 
monograph is the information concerning traditional use and/or well-established use of certain 
herbal preparations. 
Well-established use is defined in directive 2001/83/EC: 
 
By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the 
protection of industrial and commercial property, the applicant shall not be required to 
provide the results of pre-clinical tests or clinical trials if he can demonstrate that the active 
substances of the medicinal product have been in well-established medicinal use within the 
Community for at least ten years, with recognised efficacy and an acceptable level of safety in 
terms of the conditions set out in the Annex. In that event, the test and trial results shall be 
replaced by appropriate scientific literature. 
 
The definition of “Traditional use” is according directive 2004/24/EC: 
 
Article 16a 
A simplified registration procedure is hereby established for herbal medicinal products 
which fulfil all of the following criteria: 
a) they have indications exclusively appropriate to traditional herbal medicinal 
products which, by virtue of their composition and purpose, are intended and designed 
for use without the supervision of a medical practitioner for diagnostic purposes or for 
prescription or monitoring of treatment; 
b) they are exclusively for administration in accordance with a specified strenght and 
posology; 
c) they are an oral, external and/or inhalation preparation; 
d) the period of traditional use as laid down in Article 16c(1)(c) has elapsed (= at least 
30 years of medicinal use, with 15 years within the EU); 
e) the data on the traditional use of the medicinal product are sufficient; in particular 
the product proves not to be harmful in the specified conditions of use and the 
pharmacological effects of efficacy of the medicinal product are palusible on the basis 
of long-standing use and experience. 
 
Aim of the diploma thesis: 
The monograph must be supported by an assessment report reflecting the current scientific 
knowledge and presenting data on the traditional use. Therefore in the first step a 
comprehensive literature search should provide an overview on published data. In a second 
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step papers of interest should be obtained in full text. The assessment report should 
summarize the published data on topics like traditional use, pharmacology, pharmacokinetics, 
clinical trials, adverse effects followed by an interpretation by the assessor. The final outcome 
should be a draft monograph on Hypericum perforatum, which should present information on 
indication, dosage, duration of use, contraindications, interactions, use during pregnancy and 
lactation amd adverse effects separately for certain herbal preparations for well-established 
use or traditional use. The draft monograph will be published on the EMEA webside for 
public consultation for three months. The final monograph will be prepared by the rapporteur 
considering the comments received by interested parties. 
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Methodology 
 
Literature search: 
Period: March 2007 to June 2008.  
 
Electronic data search: 
Search engine: Pubmed (http://www.ncbi.nlm.nih.gov/sites/entrez);  
Keywords: Hypericum perforatum, Hypericin, Hyperforin 
Hager CD-Rom 
 
Manual search: 
University of Vienna, Pharmacy and Nutritional Sciences Library  
Medical University of Vienna, main library 
 
The Pharmacy and Nutritional Sciences Library of the University of Vienna is a valuable 
source of older handbooks of pharmacy, old pharmacopoeias and old handbooks of 
phytotherapy, which are not available from electronic sources, but are essential for the 
documentation of the traditional use. 
 
For the evaluation of the literature and elaboration of the assessment report for traditional and 
well-established use of Hypericum perforatum L I followed the guidelines of the EMEA: 
• Guideline on non-clinical documentation for herbal medicinal products applications 
for marketing authorisation (bibliographical and mixed applications) and in 
applications for simplified registration (EMEA/HMPC/32116/2005) 
• Guideline on the assessment of clinical safety and efficacy in the preparation of 
community herbal monographs for well-established and of community herbal 
monographs/entries to the community list for traditional herbal medicinal 
products/substances/preparations (EMEA/HMPC/104613/2005) 
• Procedure for the preparation of community monograph for traditional herbal 
medicinal products (EMEA/HMPC/182320/2005 rev 1) 
• Procedure for the preparation of community monographs for herbal medicinal 
products with well-established use (EMEA/HMPC/182352/2005 rev 2). 
 
The structure of the assessment report and of the monograph are defined in the template 
EMEA/HMPC/418902/2005 
 
All guidelines and templates are available at the website of the EMEA 
(http://www.emea.europa.eu/htms/human/hmpc/index.htm). 
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Results 
 
 
I  Assessment report for herbal substance(s), herbal preparation(s) or combinations 
thereof with well-established use and/or traditional use 
 
 
 II Monograph on Hypericum perforatum L., herba 
 
 
 
- 9 - 
I. ASSESSMENT REPORT 
FOR HERBAL SUBSTANCE(S), HERBAL PREPARATION(S) OR 
COMBINATIONS THEREOF WITH WELL-ESTABLISHED USE AND/OR 
TRADITIONAL USE 
 
Hypericum perforatum L., herba 
 
BASED ON ARTICLE 10A OF DIRECTIVE 2001/83/EC AS AMENDED 
(WELL-ESTABLISHED USE) 
 
BASED ON ARTICLE 16D(1) AND ARTICLE 16F AND 16H OF DIRECTIVE 
2001/83/EC AS AMENDED 
(TRADITIONAL USE) 
 
 
Herbal substance(s) (binomial scientific name 
of the plant, including plant part) 
Whole or cut, dried flowering tops of 
Hypericum perforatum L., harvested during 
flowering time. 
Herbal preparation(s)  
Pharmaceutical forms 
Herbal substance or comminuted herbal substance 
for liquid dosage forms for cutaneous use or 
liquid and solid dosage forms for oral use. 
 
Rapporteur Austria 
Assessors 
Reinhard Länger 
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I.1 INTRODUCTION 
I.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations 
thereof 
I.1.1.1 Herbal substance(s) 1: 
Hyperici herba (European Pharmacopoeia) 
 
Hyperici herba consist of the whole or cut, dried flowering tops of Hypericum perforatum L., 
harvested during flowering time. It contains not less than 0.08 % of total hypericins expressed 
as hypericins calculated with reference to the dried drug. 
 
Constituents (Wichtl 2002; Bradley 2006, Hänsel et al 2007) 
 
• Phloroglucinol derivates: 0,2-4 %, depending on the age of the herbal drug, mainly 
hyperforin and its homologue adhyperforin, furanohyperforin 
• Naphtodianthrones: 0,06-0,4 %, mainly pseudohypericin and hypericin, 
protohypericin, protopseudohypericin, cyclopseudohypericin, skyrinderivatives. The 
amount of pseudohypericin is about 2-4 times higher than that of hypericin. 
• Flavonoids: 2-4 %, mainly glycosides of the flavonol quercetin: hyperoside, rutin, 
isoquercitrin, quercitrin; also biflavones (I3,II8-Biapigenin, Amentoflavone) 
• Procyanidines: e.g. procyanidine B2, tannins with catechin skeletal (6-15 %)  
• Xanthones: in trace amounts 
• Essential oil: 0.1-0.25 %; the essential oil of dried flowering tops contains as main 
compounds 2-methyloctane (16 %) and α-pinene (10.6 %). In the essential oil of 
leaves of Indian origin 58 components were identified, α-pinene (67 %) being 
dominant; the other components included caryophyllene, geranyl acetate and nonane 
(each about 5 %) 
• Other constituents: include small amounts of chloregenic acid and other caffeoylquinic 
and p-coumaroylquinic acids, and also free amino acids. 
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3 According to the ‘Procedure for the preparation of Community monographs for traditional herbal medicinal 
products’ (EMEA/HMPC/182320/2005 Rev.2) and the ‘Procedure for the preparation of Community 
monographs for herbal medicinal products with well-established medicinal use (EMEA/HMPC/182352/2005 
Rev.2) 
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I.1.1.2 Herbal preparation(s): 
St. John’s wort dry extract, quantified extract (Pharm. Eur. ref. 07/2008:1874) 
Extraction solvents ethanol (50-80% v/v) or methanol (50-80% v/v). Content of total 
hypericins (expressed as Hypericin) 0.10-0.30%, content of flavonoids (expressed as 
rutin) minimum 6.0%, content of hyperforin maximum 6.0% and not more than the 
content stated on the label. 
 
Herbal preparations with evidence of tradition according Dir. 2004/24: 
A) Dry extract, DER 4,6-6,5:1, extraction solvent ethanol 38% v/v. This type of extract is 
in medicinal use since more than 30 years. 
B) Dry extract (DER 3.5-6:1), extraction solvent ethanol 60% (m/m): on the market in 
DE at least since 1976 
C) Dry extract (DER 5-7:1), extraction solvent ethanol 70% (m/m): on the market in DE 
at least since 1976 
D) Liquid extract (DER 1:4-20), extraction solvent vegetable oil (e.g. olive oil, sunflower 
oil, linseed oil, wheat germ oil) 
Preparation:  
According to the German “Ergänzungsbuch” to the German Pharmacopoeia 6 
(Erg.-B6. 1941): The crushed fresh flowers of Hypericum perforatum (25 
parts) are doused with olive oil (100 parts) in a white glass. The mixture is 
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allowed to ferment at a warm place. After completion of the fermentation the 
glass has to be sealed. It is then stored at a sunny place for about 6 weeks until 
the oil is bright red. The herbal substance has to be pressed out, the oil is dried 
with sodium sulfate (6 parts).  
 
According to Swiss Pharmacopoeia (1999, Pharm. Helv. 8): The comminuted 
fresh flowering tops of Hypericum perforatum are overflowed with 40.0 g 
refined sun flower oil. The mixture is reshuffled frequently; extraction and 
fermentation take place at a temperature of 15-30 °C. After 50-80 days the 
herbal substance is pressed out, the water layer is removed. It is allowed to 
dilute the oil to a maximum of 80 g of sunflower oil, the content of hypericin is 
at least 0.001% (spectrophotometric determination). 
 
According to the company ‘Caelo’, Germany: the dried herbal substance 
(according to Pharm. Eur.) is macerated with olive oil in a DER of 1:20. The 
mixture is agitated under light exposure for at least 40 hours. The content of 
hypericin is at least 0.005% (spectrophotometric determination). 
 
Constituents of Hyperici oleum 
Hyperici Oleum does not contain hypericin. By using the sunlight maceration method 
described in the supplement to DAB 6 (EB 6), lipophilic breakdown products of this 
compound are obtained which lend the oil its red colour. The stability of hyperforin is 
limited; sufficient shelf-life could only be achieved by hot maceration of dried flowers 
with eutanol G and storage in the absence of air. The action of light during preparation 
of the oil led to a rise in the content of flavonoids (Maisenbacher et al 1992).  
As a consequence the spectrophotometric determination used for the specification of 
the St. John’s wort oils mentioned above detects primarily artifacts of hypericin. 
Schempp et al (2000) used for the test of the influence of Hypericum extracts 
on skin sensitivity Hypericum oil containing 110 µg/ml Hypericin. It is not 
transparent, whether the authors determined hypericin or the oil derivatives. 
 
E) Liquid extract (DER 1: 13), extraction solvent maize oil: on the market in DE at least 
since 1976 
F) Tincture (DER 1:10), extraction solvent ethanol 45-50% v/v: The external use of a 
tincture (no further details on DER and extraction solvent) is mentioned in Irion 
(1955) as an equivalent to hypericum oil. Also Madaus (1938) mentions the use of a 
tincture, details about the DER are lacking. A tincture with a DER of 1:10 (extraction 
solvent ethanol 45-50% v/v) is mentioned as traditional herbal preparation in Barnes et 
al (2002) and Gruenwald et al (2004). 
G) Tincture (DER 1:5), extraction solvent ethanol 50% v/v: mentioned in Bradly (2006). 
The evidence of tradition of this tincture has to be proved. 
 
H) Liquid extract DER 1:2, extraction solvent ethanol 50% 
The product ‘Hyperforat-drops’, contains a liquid extract with DER of 1:2, extraction 
solvent ethanol 50% (no details v/v or m/m). This is in contrast to details given in the 
review of Linde (2007) with respect to the DER: Hyperforat is cited in the study with 
a DER of 5-7:1, which would indicate a dry extract. This difference is due to obvious 
incorrect data in the German “Rote Liste”. The first clinical study with this liquid 
extract is published 1979, therefore when the monograph on hypericum will be 
published the extract is in medicinal use at least 30 years.  
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I) Liquid extract 1: 5-7, ethanol 50%. Trade name Psychotonin, since 1963 in medicinal 
use. 
J) Expressed juice from the fresh herb (DER 1.25-2.5:1): on the market in DE at least 
since 1976 
K) Comminuted herbal substance: cut herbal substance used for tea preparation; 
powdered herbal substance in solid dosage forms for oral use on the market in DE at 
least since 1976 
 
Further liquid extracts: 
 
Since the edition 1993 of Hager’s Handbuch (Hänsel et al 1993) a liquid extract with a 
DER 1:6, extraction solvent ethanol 70% is mentioned. This type of extract is not 
mentioned in previous literature. The period of 30 years of medicinal use is therefore 
not fulfilled.  
 
The request for marketed products in the EU revealed that numerous further extracts are 
on the market. However, they neither do fulfil the criteria for traditional use nor are 
supported by clinical evidence. 
 
Influence of the extraction solvent on the composition of the extract: 
When using extraction solvents containing more than 50% of ethanol or methanol in water the 
content of hypericin in the extract seems to be very similar independent of the actual 
concentration of the extraction solvent. In contrast the extraction of hyperforin and 
adhyperforin depends strongly on the concentration of the extraction solvent. Best yield (60% 
of the hyperforin in the herbal substance, 45% of adhyperforin in the herbal substance) is 
achieved with 70% (e.g. ethanol), while with 50% ethanol only 20% of hyperforin and no 
adhyperforin are extracted (Meier 1999). 
I.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)2 
Not applicable 
I.1.1.4 Vitamin(s)3 
Not applicable 
I.1.1.5 Mineral(s)3 
Not applicable 
 
I.1.2 Information on period of medicinal use in the Community regarding the specified 
indication 
 
I.1.2.1 Type of tradition, where relevant 
 
European tradition 
 
I.1.2.2 Bibliographic/expert evidence on the medicinal use 
 
                                                 
2  According to the ‘Guideline on the clinical assessment of fixed combinations of herbal substances/herbal 
preparations’ (EMEA/HMPC/166326/2005) 
3  Only applicable to traditional use 
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I.1.2.2.1 Evidence regarding the indication/traditional use 
 
Traditional indications for oral use of herbal teas liquid extracts (extraction solvent 
ethanol) and dry extracts 
 
Nervous system disorders, psychiatric disorders: 
Indication References 
Psychovegetative disturbances Hamacher et al (2003), Hänsel (1993), Wichtl (2004), 
Blaschek et al (2006), Hänsel et al (1993), Gruenwald et 
al (1998), Gruenwald et al (2004), Commission E 
monographs (1998), Dingermann et al (2004), DAC 
(1991-1999) 
Mood depression Hamacher et al (2003), Hänsel (1993), Bradley (2006), 
Irion (1955), Blaschek et al (2006), Hänsel et al (1993), 
Auster et al (1958), Gruenwald et al (1998), Gruenwald 
et al (2004), Commission E monograpsh (1998), 
Dingermann  et al (2004), Hänsel et al (1988), DAC 
(1991-1999), Flamm et al (1940) 
Mild depression Escop 2003 
Anxiety and/or nervous 
restlessness 
Hänsel (1993), Wichtl (2004), Bradley 2006 (including 
menopausal anxiety), Blaschek et al (2006), Hänsel et al 
(1993), Madaus (1938), Gruenwald et al (1998), 
Gruenwald et al (2004), Barnes et al (2002), 
Commission E monographs (1998), Dingermann et al 
(2004), Hänsel et al (1988), DAC (1991-1999), 
Martindale (2002) (particularly if associated with the 
menopause) 
Insomnia  Gerlach (2008), Irion (1955), List et al (1976), Madaus 
(1938), Barnes et al (2002), Hänsel et al (1988), 
Martindale (2002) 
Support of emotional balance Gerlach (2008), ESCOP (2003) 
‘Weak nerves’, vegetative 
dystonia 
Gerlach (2008), Irion (1955), 
Agitation, excitability, irritability List et al (1976), Barnes et al (2002), Upton (1997) 
After mental efforts  Madaus (1938) 
Neuralgia, Neurasthenia List et al (1976), Madaus (1938), Barnes et al (2002), 
Flamm et al (1940), WHO monographs (2002) 
Traumatic damages of nerves, 
paralysis 
Madaus (1938) 
Migraine, headache Flamm et al (1940), WHO monographs (2002) 
Sciatica  Barnes et al (2002), WHO monographs (2002) 
 
Gastrointestinal disorders  
Indication References 
Gastritis Wichtl (2002), Blaschek et al (2006), Hänsel et al 
(1993), Gruenwald et al (2004), Böhme (2006) 
Ulcers, dyspepsia WHO monographs (2002) 
Unspecific catarrhs of the gastro-
intestinal tact 
Gerlach (2008), Irion (1955), Flamm et al (1940), 
Hänsel et al (1988) 
Nervous gastric diseases Gerlach (2008), Blaschek et al (2006), Hänsel (1993) 
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Abdominal pain Madaus (1938) 
Diarrhoea Wichtl (1984), List et al (1976), Blaschek et al (2006), 
Hänsel et al (1993), Madaus (1938), Gruenwald et al 
(2004), Flamm et al (1940), Karsten et al (1962) 
Haemorrhoids Irion (1955), List et al (1976), Flamm et al (1940), WHO 
monographs (2002) 
 
Hepatobiliary disorders 
Indication References 
Gallbladder diseases Wichtl (2004), Irion (1955), List et al (1976), Blaschek 
et al (2006), Hänsel et al (1993), Madaus (1938), 
Gruenwald et al (2004), Böhme (2006), WHO 
monographs (2002) 
As a choleretic Blaschek et al (2006), Hänsel et al (1993) 
 
Renal and urinary disorders 
Indication References 
Nocturnal enuresis Gerlach (2008), Wichtl (1984), Irion (1955), List et al 
(1976), Blaschek et al (2006), Hänsel et al (1993), 
Madaus (1938), Gruenwald et al (2004), Flamm et al 
(1940), Dingermann et al (2004), Schneider (1990) 
Kidney stones, bladder stones, 
inflammations of the urogenital 
tract 
Irion (1955), Flamm et al (1940), WHO monographs 
(2002) 
Irritable bladder, incontinence Hamacher et al (2003), WHO monographs (2002) 
As a diuretic Wichtl (1984), List et al (1976), WHO monographs 
(2002) 
 
Respiratory, thoracic and mediastinal disorders 
Indication References 
Cough, bronchitis, asthma Irion (1955), Blaschek et al (2006) Hänsel et al (1993), 
Madaus (1938), Gruenwald et al (2004), Flamm  et al 
(1940), WHO monographs (2002) 
Common cold WHO monographs (2002) 
 
Infections and infestations 
Indication References 
Worm infestations Blaschek et al (2006), Hänsel et al (1993), Gruenwald et 
al (2004), Flamm et al (1940), Zörnig (1911) 
As an antimalaria agent WHO monographs (2002) 
 
Endocrine disorders 
Indication References 
Polymenorrhoea, 
oligomenorrhoea, 
dysmenorrhoea, endometritis 
Madaus (1938), Irion (1955), Flamm et al (1940), 
Heinrich et al (2004) 
As emmenagogue WHO monographs (2002) 
Diabetes Irion (1955), Auster et al (1958), WHO monographs 
(2002) 
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Musculoskeletal and connective tissue disorders 
Indication References 
Rheumatism Wichtl (1984), Blaschek et al (2006), Hänsel et al 
(1993), Auster et al (1958), Gruenwald et al (2004) 
 
Metabolism and nutrition disorders 
Indication References 
Gout  Wichtl (1984), Blaschek et al (2006), Hänsel et al 
(1993), Gruenwald et al (2004) 
Metabolic disorders List et al (1976) 
 
Traditional indications for oral use of liquid extracts (extraction solvent vegetable oil): 
Indication References 
Dyspepsia Hamacher et al (2001), Blaschek et al (2006), Hänsel et 
al (1993), Gruenwald et al (1998), Gruenwald et al 
(2004), Commission E monographs (1998), DAC (1991) 
Nervous gastric diseases Gerlach (2008), Blaschek et al (2006), Hänsel et al 
(1993)  
As a choleretic Blaschek et al (2006), Hänsel et al (1993) 
Abdominal pain  Madaus (1938) 
 
 
Discussion and assessment of traditional indications for oral use: 
Since the hypericum oil differs considerably in the nature of the constituents from aqueous 
and ethanolic liquid extracts these types of herbal preparations are discussed separately. 
a) Aqueous extracts (herbal teas), liquid extracts prepared with ethanol, dry extracts: 
Infusions prepared with water are widely used in the traditional medicine at least in 
Central Europe (Gerlach 2008). The indication ‘depression’ is unknown in traditional 
medicine; Hypericum is used in order to ‘strengthen the nerves’, to restore emotional 
balance. The wording which is found in literature reflects this fact, although put into 
different words. This traditional indication is plausible because of the pharmacological 
and clinical data which are available for isolated compounds and alcoholic extracts of 
Hypericum perforatum. 
The numerous further traditional indications mentioned in the literature for these kinds 
of extracts are not plausible. 
Since for the indication of a traditional herbal medicinal product terms like 
‘depression’ or ‘depressed mood’ are not suitable, special care is taken to the wording.  
Proposals: 
Somatoform disorders (ICD-10 F45.0): 
The main feature is repeated presentation of physical symptoms together with 
persistent requests for medical investigations, in spite of repeated negative 
findings and reassurances by doctors that the symptoms have no physical basis. 
If any physical disorders are present, they do not explain the nature and extent 
of the symptoms or the distress and preoccupation of the patient.  
 
Neurasthenia (ICD-10 F48.0) 
Considerable cultural variations occur in the presentation of this disorder, and 
two main types occur, with substantial overlap. In one type, the main feature is 
a complaint of increased fatigue after mental effort, often associated with some 
decrease in occupational performance or coping efficiency in daily tasks. The 
mental fatiguability is typically described as an unpleasant intrusion of 
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distracting associations or recollections, difficulty in concentrating, and 
generally inefficient thinking. In the other type, the emphasis is on feelings of 
bodily or physical weakness and exhaustion after only minimal effort, 
accompanied by a feeling of muscular aches and pains and inability to relax. In 
both types a variety of other unpleasant physical feelings is common, such as 
dizziness, tension headaches, and feelings of general instability. Worry about 
decreasing mental and bodily well-being, irritability, anhedonia, and varying 
minor degrees of both depression and anxiety are all common. Sleep is often 
disturbed in its initial and middle phases but hypersomnia may also be 
prominent. 
 
Adjustment disorders (ICD-10 F43.2) 
States of subjective distress and emotional disturbance, usually interfering with 
social functioning and performance, arising in the period of adaptation to a 
significant life change or a stressful life event. The stressor may have affected 
the integrity of an individual's social network (bereavement, separation 
experiences) or the wider system of social supports and values (migration, 
refugee status), or represented a major developmental transition or crisis 
(going to school, becoming a parent, failure to attain a cherished personal goal, 
retirement). Individual predisposition or vulnerability plays an important role 
in the risk of occurrence and the shaping of the manifestations of adjustment 
disorders, but it is nevertheless assumed that the condition would not have 
arisen without the stressor. The manifestations vary and include depressed 
mood, anxiety or worry (or mixture of these), a feeling of inability to cope, 
plan ahead, or continue in the present situation, as well as some degree of 
disability in the performance of daily routine. Conduct disorders may be an 
associated feature, particularly in adolescents. The predominant feature may be 
a brief or prolonged depressive reaction, or a disturbance of other emotions 
and conduct. 
 
All these three types of disorders reflect partly the traditional oral use Hypericum. The 
definition of the somatoform disorders includes characteristics which are not suitable 
for THMPs. Particularly the persistent request for medical investigation is in contrast 
to the concept that the products are intended for use without medical supervision. 
The traditional use seems to be covered in a most suitable way by the definition of 
neurasthenia. 
The plausibility of the efficacy in this traditional indication is supported by an 
observational study (Grube et al 1996). Hypericum dry exctract LI 160 was 
administered corresponding to 900 µg Hypericine daily (= app. 540 mg extract) to 
patients with mild temporary depressed mood.  
Additionally the indication should be clearly different from the proposed health claims 
for food supplements (contributes to emotial balance and general wellbeing; 
contributes to optimal relaxation; helps to support relaxation and mental and physical 
wellbeing; helps to maintain a healthy sleep; helps maintain a positive mood). 
 
Proposed traditional indication (oral use, aqueous extracts, liquid ethanolic extracts, 
dry extracts) 
Indication 1) 
Traditional herbal medicinal product for the symptomatic relief of temporary 
neurasthenia (e.g. difficulty in concentrating, inefficient thinking, feeling of physical 
weakness and exhaustion after minimal effort, gastrointestinal discomfort). 
. 
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The product is a traditional herbal medicinal product for use in the specified indication 
exclusively based upon long-standing use. 
 
b) Liquid extracts prepared with vegetable oil (hypericum oil): 
The indications mentioned in the references cannot be explained by the constituents of 
the hypericum oil, data from pharmacological experiments are lacking. Therefore the 
mentioned indications are not plausible. There is no traditional indication for the oral 
use of hypericum oil. 
 
Traditional indications for cutaneous use of liquid extracts (extraction solvent vegetable 
oil): 
 
Skin and subcutaneous tissue disorders 
Indication References 
First degree 
burns, sunburn 
Gerlach (2008), Wichtl (1984), Wichtl (2004), Bradley (2006), Irion 
(1955), Flamm et al (1940), Schneider (2004), Wagner et al (1999), 
Böhme (2006), WHO monographs (2002), Hamacher et al (2001), 
Hamacher et al (2006), Blaschek et al (2006), Hänsel et al (1993), 
Gruenwald et al (1998), Gruenwald et al (2004), Comission E 
monographs (1998), DAC (1991), DAC (1998) 
Wound healing 
 
Gerlach (2008), Wichtl (1984), Wichtl (2004), Bradley (2006), Irion 
(1955), Hager (1878), Fischer et al (1902), Frerichs et al (1938), List et al 
(1976), Auster et al (1958), Flamm et al (1940), Wagner et al (1999), 
Schneider (1990), Karsten et al (1962), WHO monographs (2002), 
Hamacher et al (2001), Hamacher et al (2006), Blaschek et al (2006), 
Hänsel et al (1993), Gruenwald et al (1998), Gruenwald et al (2004), 
Comission E monographs (1998), DAC (1991), DAC (1998), Madaus 
(1938) 
Gingivits, 
stomatitis 
Gerlach (2008), Hänsel et al (1972) 
Fibrositis Barnes et al (2002) 
Neurodermatitis Wagner et al (1999) 
Eczema Irion (1955) 
Prevention of 
decubitus 
Hänsel et al (1988), Hänsel et al (2007) 
Shingles, viral 
infections 
Bradley (2006), WHO monographs (2002) 
 
Musculoskeletal and connective tissue disorders 
Indication References 
Myalgia  
 
Hamacher et al (2001), Hamacher et al (2006), Länger et al (2001), 
Blaschek et al (2006), Hänsel et al (1993), Gruenwald et al (1998), 
Gruenwald et al (2004), Comission E monographs (1998), DAC (1991), 
DAC (1998), Flamm et al (1940), Wagner et al (1999) 
Rheumatism Gerlach (2008), Irion (1955), Flamm et al (1940), Hager (1878), 
Blaschek et al (2006), Hänsel et al (1993), Wagner et al (1999), Auster et 
al (1958) 
Lumbago Blaschek et al (2006), Hänsel et al (1993), Flamm et al (1940), Madaus 
(1938) 
Ischialigia, 
neuralgia 
Irion (1955), Flamm et al (1940), Böhme (2006) 
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Articular pain Gerlach (2008) 
Sprains  Flamm et al (1940), Madaus (1938) 
Bruises Bradley (2006), Irion (1955), Flamm et al (1940) 
Swellings Bradley (2006), Flamm et al (1940), Madaus (1938)  
 
Metabolism and nutrition disorders 
Indication References 
Gout  Gerlach (2008), Irion (1955), Flamm et al (1940), Madaus (1938)  
 
Traditional indications for cutaneous use of liquid extracts (extraction solvent ethanol): 
Skin and subcutaneous tissue disorders 
Wound healing Gerlach (2008), Irion (1955) 
 
Traditional indications for cutaneous use of liquid extracts (extraction solvent water): 
Skin and subcutaneous tissue disorders 
Wound healing WHO monographs (2002) 
 
 
Discussion and assessment of traditional indications for cutaneous use: 
The traditional use of liquid preparations of hypericum for wound healing is supported by 
pharmacological data. Anti-inflammatory activity, analgesic activity, adstringent activity and 
antibacterial activity are documented, in vivo-data are poor, clinical data are lacking. In 
contrast the traditional use for the treatment of symptoms caused by an injury or related to 
rheumatism is not yet plausible. Antiviral effects are documented for several types of viruses, 
but not for Varicella zoster. Therefore the traditional use in the treatment of shingles cannot 
be supported. 
 
Proposed traditional indication (cutaneous use, liquid extracts, extraction solvents 
vegetable oil, ethanol or water) 
Indication 2) 
Traditional herbal medicinal product for the symptomatic treatment of minor 
inflammations of the skin (such as sunburn) and as an aid in healing of minor wounds. 
The product is a traditional herbal medicinal product for use in the specified indication 
exclusively based upon long-standing use. 
 
 
I.1.2.2.2 Evidence regarding the specified posology 
Oral administration 
 
Comminuted herbal substance 
The single dose for tea preparation is 1 teaspoon per cup, which is equivalent to 1.8 to 2 g of 
herbal substance. The recommendation of the daily dose is 1-2 cups equivalent to 1.8 to 4 g of 
herbal substance (Wichtl 2004, Hänsel et al 1993, ESCOP 2003), only few references 
recommend higher daily dosages (Duke 2002: up to 8 g; Madaus 1983: up to 7 g; Irion 1955 
and Barnes et al 2002: up to 12 g). 
 
Proposal for the posology of the comminuted herbal substance for tea preparation: 
Adults, elderly: single dose 2 g; daily dose 4 g 
Children and adolescents: Since no data on the safe traditional use in children are 
available the use in children and adolescents is not recommended. 
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The powdered herbal substance is in medicinal use in solid dosage forms longer than 30 
years. The proposed posology (single dose 300-500 mg, daily dose 900-1000 mg) reflects the 
posology of the authorized products. 
 
Herbal preparations: 
Dry extracts: traditionally dry extracts are administered in considerably lower doses than 
those used for the treatment of mild to moderate depression. The herbal preparation type B 
was traditionally administered in a single dose of 120 mg and a daily dose of 360 mg. A daily 
dose of 252 mg showed no beneficial effects in the treatment of mild major depression 
compared to placebo. Therefore a single dose of 60-180 mg and a daily dose of 180-360 mg 
of dry extracts are proposed for traditional use. 
Tincture (DER 1:5): 3-4.5 ml daily dose (Bradley 2006) 
Tincture (DER 1:5) (= ESCOP 2003, posology with reference to a product from Steigerwald): 
3-4.5 ml daily = equivalent to 0.6 – 0.9 g herbal substance. 
Tincture (DER 1:10), 45% ethanol: 2-4 ml 3 x daily (Barnes et al 2006, Duke 2002) = 
equivalent to 0.6 – 1.2 g herbal substance. 
Tincture (DER 1:2): Single dose 0.8-1.2 ml, daily dose 2.4-3.6 ml.  
Tincture (DER not given): 10-15 drops (= app. 0.5-0.75 ml), 2-3 x daily (= 1-2.25 ml) 
(Madaus 1938). Because of the lack of data of the DER this posology cannot be considered. 
The posology of the further mentioned herbal preparations reflects the posology of the 
authorized products. 
 
Children and adolescents: Since no data on the safe traditional use in children are available 
the use in children and adolescents is not recommended. 
 
Cutaneous administration 
Strength of the preparations: 
Hypericum oil is administered undiluted. 
Hypericum tea prepared with a DER of 1:5 (WHO monographs 2002) 
 
Children and adolescents: Since no data on the safe traditional use in children are available 
the use in children and adolescents is not recommended. 
 
 
I.2 NON-CLINICAL DATA 
I.2.1 Pharmacology 
I.2.1.1 Overview of available data regarding the herbal substance(s), herbal preparation(s) 
and relevant constituents thereof 
I.2.1.1.1 Effects associated with depression 
The mechanisms of action as well as the responsible compounds of hypericum extracts are 
still under discussion. Several actions contributing to a clinical efficacy are reported: blockade 
of the reuptake of serotonin, noradrenalin and dopamine; up regulation of postsynaptic 5-HT1 
and 5-HT2 receptors and of dopaminergic receptors; increased affinity for GABAergic 
receptors. Constituents which contribute to the activity are hypericin, pseudohypericin, 
flavonoids, and oligomeric procyanidins. The relevance of hyperforin is discussed 
controversially. As a consequence the entire extract has to be considered as the active 
substance. 
 
Effects of constituents (primarily according to a review from Butteries et al 2003) 
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Flavonoids, Bioflavonoid 
In-vitro the flavonols inhibit the monoaminooxidase (MAO), a fraction rich in flavonols also 
inhibited the catechol-O-methyltransferase (COMT). The concentrations which were 
necessary to achieve the results were considerably higher than concentrations which could be 
expected in therapeutic dosages. 
Amentoflavon, which occurs only in traces in the flowers, inhibits in very low concentrations 
the binding of flumazenil on the benzodiazepine binding sites of the GABA receptor 
(Baureithel et al 1997) as well as to the δ-subunit of the opioid receptor. I3,II8 Biapigenin, 
which is present in much higher concentrations, is not investigated up to now, because it is 
commercially not available. 
A flavonoid fraction, free of hypericins and hyperforin, induced a reduction of the β-receptors 
in the frontal cortex of the rat brain in similar manner like imipramin. 
It is not known whether the flavonoids or their metabolites are responsible for these effects. 
Hyperosid directly stimulates the endocytosis of β1-receptors and reduces their lateral 
mobility (Häberlein et al 2008). 
Quercetin (10 – 40 mg/kg) altered dose-dependently the pattern in an electropharmacogram of 
rats, the changes resembled those of the MAO A inhibitor moclobemide and the MAO B 
inhibitor selegiline (Dimpfel 2008). 
 
Naphthodianthrones 
Pure naphthodianthrones are only poorly soluble in water. The solubility is increased by 
compounds of the extract. For example procyanidines are able to increase solubility in water 
10-fold. Rutin and hyperosid may also contribute to the better solubility of hypericin in 
extracts. 
Hyperosid and the procyanidines increase the serum level of hypericin considerably. 
Isolated hypericin has no influence on the MAO A and B. In-vitro it inhibits the dopamine-β-
hydroxylase, it interacts with β-adrenergic receptors and possesses a high affinity to the σ-
receptor as well as to the D3-receptor. 
Hypericin alters the concentration of several neurotransmitters after 8 weeks of treatment 
comparable to imipramine. 8 weeks treatment also increased the serotonin concentration in 
the hypothalamus, while the concentration of metabolites of dopamine is reduced. Hypericin 
induces a reduction of the β-receptors in he frontal cortex of the rat brain, after 8 weeks of 
treatment a significant change could be observed.  
Hypericin reduced, similar to imipramine, the expression of mRNA of the corticotrophin 
releasing hormone in the hypothalamus as well as the ACTH and corticosterone levels in the 
plasma of rats. An overview presenting chemical and biological properties of hypericin is 
published by Lavie et al (1995). 
 
Phloroglucinol derivatives 
Müller et al (1998) and Chatterjee et al (1998) revealed that hyperforin plays an important 
role in the inhibition of neurotransmitter reuptake. In vitro the IC50 value for the inhibition of 
the synaptosomal reuptake of serotonin, dopamine, noradrenaline, GABA and glutamate 
caused by hyperforin is in the range of 80 to 1234 nM. After a daily intake of 900 mg of 
hypericum extract a blood level of 180 nM of hyperforin was detected. Therefore it could be 
concluded that sufficient amounts of hyperforin for the inhibition of the reuptake of some 
neurotransmitters could be achieved during therapy. 
Several mechanisms for these effects are in discussion: inhibition of calcium channels of the 
P-type, a reserpin-like action, increase of the intracellular sodium concentration. 
Isolated hyperforin did not influence the density of β-receptors in rats, while an extract rich in 
hyperforin induced a down-regulation of the β-receptor density. 
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Hyperforin directly causes the endocytosis of β1-receptors and reduces their lateral mobility 
(Häberlein et al 2008). 
 
 
Xanthones 
Due to the low content of xanthones in the herbal substance (about 0.0004%) it is not likely 
that the experimentally documented inhibition of MAO A and B is of clinically relevance. 
 
Effects of extracts (examples of publications) 
The results on MAO inhibition are controversial. At concentration of 10-4 to 10-3 mol/l of a 
methanolic extract (Bladt et al 1994) and of a methanolic extract (Thiede et al 1994) MAO 
could be inhibited up to 82%. In a later study a methanolic extract exhibited a rather weak 
potency as MAO inhibitor in vitro (Müller et al 1997). 
 
The inhibition of synaptosomal reuptake of several neurotransmitters could be demonstrated 
for different kinds of extracts (different extraction solvent, different amounts of hypericin, 
hyperforin). 
 
Long-term treatment of rats with a methanolic extract (500 mg/kg p.o.) significantly increased 
the 5-HT levels in the hypothalamus of rats; the 5-HT turnover was significantly lowered in 
hippocampus and hypothalamus (Butterweck et al 2002).  
Misane et al (2001) found that an ethanolic extract given in high doses affects the neuronal 5-
HT uptake more like tricyclic antidepressants than SSRIs.  
Calapai et al (2001) investigated an extract standardised to 50% flavonoids, 0.3% hypericin 
and 4.5% hyperforin. After acute oral administration (250 – 500 mg/kg) dose-dependently the 
contents of 5-HT and 5-hydroxyindolacetic acid (5-HIAA) were significantly enhanced in all 
brain regions examined. Noradrenalin and dopamine levels were significantly increased in the 
diencephalon; in the brainstem only noradrenalin was significantly enhanced. 
The down regulation of β-receptors could be demonstrated with an ethanolic extract (0.2% 
hypericin) dose dependently (Kientsch et al 2001). 
A methanolic extract (4.5% hyperforin) interacted with a GABA A receptor, an extract rich in 
hyperforin did not show an interaction. Data on the inhibition of specific bindings to the 
dopamine transporters indicate that the hyperforin content cannot explain effects of extracts 
on receptors (Gobbi et al 2001). 
A methanolic extract could also inhibit the binding of flumazenil to the benzodiazepine 
binding site of the GABA A receptor in vitro. 
Simbrey et al (2004) used quantitative radioligand receptor binding studies to examine the 
effects of short-term (2 wks) and long-term (8 wks) administration of different hypericum 
extracts and constituents on β-adrenergic binding in rat frontal cortex. The effects were 
compared to those of the standard antidepressants imipramine and fluoxetine. A lipophilic 
CO2 extract decreased beta-AR-binding (13%) after two weeks and slightly increased the 
number of β-receptors after 8 weeks (9%). Short-term treatment with the methanolic 
hypericum extract decreased β-receptor-binding (14%), no effects for this extract were 
observed after 8 weeks. Treatment with hypericin led to a significant down-regulation (13%) 
of β-receptors in the frontal cortex after 8-weeks, but not after 2 weeks, while hyperforin 
(used as trimethoxybenzoate), and hyperoside were ineffective in both treatment paradigms. 
Compared to the hypericum extracts and single compounds the effect of imipramine on β-
receptor-binding was more pronounced in both treatment paradigms.   
Teufel-Mayer et al (1997) could demonstrate that a methanolic extract significantly increased 
the numbers of 5-HT receptors, whereas the affinity of these receptors remained unchanged. 
Hypericum extract inhibited the binding of naloxone to the µ- and κ-opioid receptor (IC50 
values 25 and 90 µg/ml). Isolated flavonoids like quercetin, kaempferol as well as quercitrin 
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did not inhibit naloxone binding. The authors suggest that this inhibition may contribute to the 
anti-depressant activity (Simmen et al 1998). 
 
I.2.1.1.2 Antidepressant activity in animal models 
Forced swimming test 
In the FST pure naphthodianthrones were active in high concentrations only, after addition of 
a fraction rich in procyanidines (which is itself inactive in the FST) was hypericin active in a 
concentration of 0.009 mg/kg (Butterweck et al 1998).  
Hyperosid, Isoquercitrin and miquellianin showed activity in low concentrations (0.6 mg/kg) 
in the FST. Rutin, when administered as isolated compound, has no activity in the FST. 
However, extracts with a low content of rutin show only a weak activity in the FST, but when 
pure rutin is added to the extract, an activity could be demonstrated. Unfortunately the 
contents of the naphthodianthrones were not presented in the study (Butterweck et al 2000). 
Daily administration of 3 mg/kg isorhamnetin, a main metabolite from quercetin, for 9 days 
induced a statistically significant decrease in the immobility time in the forced swimming test 
(Paulke et al 2008). 
Noldner et al (2002) found that an ethanolic extract (doses 30-300 mg/kg, 7 days oral 
treatment) shortened the spent time immobile in a dose dependent manner, while a methanolic 
extract was inactive. After addition of rutin to the methanolic extract a strong effect 
comparable to the ethanolic extract could be demonstrated. 
Beijamini et al (2003) investigated the same methanolic extract. The rats received 150 to 500 
mg/kg extract in 3 portions starting 24 hours before the experiment. All doses significantly 
reduced the immobility time. 
Two different hydroethanolic extracts (4.5% and 0.5% hyperforin) and a stable salt of 
hyperforin were tested in the forced swimming test by Cervo et al (2002). All test substances 
caused a significant reduction of immobility; the effect was more pronounced in the extract 
containing more hyperforin. The authors therefore conclude that hyperforin plays an 
important role in the antidepressant-like activity. 
Calapai et al (2001) found that an extract standardised to 50% flavonoids, 0.3% hypericin and 
4.5% hyperforin was able to reduce the immobility time by about 30-40% compared to 
control. The effect was antagonised by the coadministration of sulpiride and metergoline. The 
effect was also significantly ower in animals pre-treated with 6-hydroxydopamine, which 
destroys noradrenergic neurons. The authors suggest that the action is probably mediated by 
serotonergic, noradrenergic and dopaminergic system activation. 
 
Learned-helplessness paradigm 
Chatterjee et al (1998) compared an ethanolic extract (4.5% hyperforin) and a supercritical 
CO2 extract (38.8% hyperforin). Oral doses of 300 mg/kg/day of the ethanolic extract and 30 
mg/kg/day of the CO2 extract were almost equieffective to 10 mg/kg/day of imipramine (52% 
reduction). 
 
Model of escape deficit 
Usai et al (2003) compared 2 hydroethanolic extracts (4.5% hyperforin, 7.47% hyperforin). 
Both extracts exhibit a strong protective effect to prevent the development of escape deficit in 
rats. The extract with 4.5% hyperforin was effective in doses 8 times lower than of the other 
extract. 
 
I.2.1.1.3 Anxiolytic effects 
Kumar et al (2000) reported anxiolytic effects of a hypericum extract (ethanol 50%) of Indian 
origin in animal models, the dosage was relatively high (100 and 200 mg / kg p.o.). 
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Flausino et al (2002) investigated the effects of acute and chronic oral treatment with 
Hypericum perforatum L. (HP LI 160, 62.5-500 mg/kg) in rats submitted to different anxiety 
models: the elevated T-maze (for inhibitory avoidance and escape measurements), the 
light/dark transition, and the cat odor test. These models were selected for their presumed 
capacity of evidencing specific subtypes of anxiety disorders as recognized in clinical 
practice. The results showed that acute HP (125 mg/kg) impaired elevated T-maze inhibitory 
avoidance, an anxiolytic effect, without altering escape performance. Chronic HP (250 
mg/kg) enhanced avoidance latencies only in animals that were preexposed to the open arms 
of the maze. Preexposure shortens escape latency, improving it as an escape index. 
Differently from the reference drug imipramine (IMP, 15 mg/kg), chronic HP did not impair 
escape from the open arms of the maze. On the other hand, similarly to IMP, the extract 
increased the number of transitions between the two compartments in the light/dark transition 
model. Treatment regimens with HP and IMP did not alter behavioral responses of rats to a 
cloth impregnated with cat odor. These observations suggest that HP LI 160 exerts anxiolytic-
like effects in a specific subset of defensive behaviors, particularly those related to 
generalized anxiety. 
 
The aim of a study from Beijamini et al (2003) was to evaluate the putative 
antipanic/anxiolytic effect of standardised H. perforatum extract (LI 160) on rats tested in the 
elevated T-maze, an animal model of innate (panic) and learned (generalised) anxiety, at 
doses that exhibit antidepressant-like activity. H. perforatum (150, 300 and 500 mg/kg, 
administered orally 24, 18 and 1h before the test) decreased the immobility time in the forced 
swim test. Rats were treated orally with H. perforatum (150 or 300 mg/kg) or paroxetine 
(5mg/kg) 24, 18, and 1h before being tested in the elevated T-maze (subacute treatment). 
Immediately after this test, the animals were submitted to the open field to evaluate locomotor 
activity. Paroxetine was used as a positive control. Other groups of animals were submitted to 
the same drug treatment for 7 days (subchronic treatment). Paroxetine (5mg/kg) impaired 
inhibitory avoidance after subacute treatment, while subchronic administration increased one-
way escape latency. Subacute treatment with H. perforatum (300 mg/kg) exerts a partial 
anxiolytic-like effect in the inhibitory avoidance task. Repeated administration of H. 
perforatum (300 mg/kg) induced an anxiolytic effect (decreased inhibitory avoidance) and an 
antipanic effect (increased one-way escape). No effect on locomotor activity was found with 
any treatment. Thus, the results suggest that H. perforatum extract could exert an anxiolytic 
and antipanic effect.   
 
Grundmann et al (2006) used exposure to an open field (OF) as inescapable stressor to mice. 
Exposure of male BL6/C57J mice to OF stress significantly increased body temperature 
(DeltaT = 1.8 +/- 0.13 degrees C, p < 0.05). Anxiolytic drugs (the benzodiazepine diazepam; 
5 mg/kg, and the 5HT (1A) receptor agonist buspirone; 10 mg/kg) significantly reduced 
DeltaT, whereas antidepressants (imipramine and fluoxetine) had no effect on DeltaT. Oral 
administration of hypericum extract significantly reduced DeltaT in doses of 250 and 500 
mg/kg. Higher (750 and 1000 mg/kg) as well as a lower dose (125 mg/kg) did not affect 
DeltaT after stress, indicating a U-shaped dose-response curve. Hypericin (0.1 mg/kg, p. o.) 
administered 60 min prior to testing significantly decreased DeltaT (p < 0.05) whereas 
hyperforin (1 - 10 mg/kg, p. o.) had no effect in this test paradigm. The flavonoids 
hyperoside, isoquercitrin and quercitrin (all at 0.6 mg/kg, p. o.) and rutin (1 mg/kg, p. o.) only 
partially blocked OF-induced hyperthermia. If compared to all other flavonoids, the quercetin 
3-O-glucuronide miquelianin (1.2 mg/kg, p. o.) was the most potent compound tested in this 
experimental design. From the biflavonoids in hypericum, only amentoflavone decreased 
SIH-induced hyperthermia in a dosage of 0.1 mg/kg. These findings could be interpreted as 
putative anxiolytic effects of hypericum extract and single consituents. 
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I.2.1.1.4 Neuroprotection, memory impairment, nootropic effects 
Kaltschmidt et al (2002) analyzed the effect of hypericin on NF-κB activation. Hypericin 
alone was able to induce short-time activation of NF-κB, which declined to basal levels after 
24 h. Cell death was induced by hypericin at a concentration of 10 µM. A profound 
synergistic action in inducing apoptosis was detected in co-treatment of hypericin together 
with FeSO4. In contrast, hypericin in low concentrations was able to partly prevent cell death 
induced by amyloid-beta-peptide (Abeta). Hypericin (10 µM) synergistically enhanced Abeta 
neurotoxicity. The data describe NF-κB in the same primary neuronal culture as stimulus-
dependent, anti-apoptotic, or pro-apoptotic factor.   
 
Extracts of Hypericum perforatum exhibited upgrading and significant protective effects on 
the trauma of PC12 cells induced by 200 µM H2O2 in a dose-dependent manner within 24-
hour treatment (Lu et al 2004). Cell viability was assessed by the MTT method, and in situ 
cellular hydrogen peroxide (H2O2)-induced oxidative stress was examined by measurement of 
reactive oxygen species (ROS) formation using CDCFH procedures. Intra- and extra-cellular 
ROS levels decreased significantly to 71.9% and 50.0% of the control at a moderate 
concentration of 20 µg/ml, respectively, suggesting that hypericum extract could easily enter 
the cells and play important roles in reducing ROS levels. Our results were proved by 
detection of DNA fragmentation and inspection of cell morphology of PC12 cells. Hypericum 
extract can obviously block DNA fragmentation and prevent the cells from shrinking and 
turning round of H2O2-induced apoptosis in PC12 cells at concentrations of 10 approximately 
100 µg/ml. The authors conclude that hypericum extracts may be a candidate for application 
in neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease. 
 
Genovese et al (2006) evaluated the effect of H. perforatum (given at 30 mg / kg) in an 
experimental animal model of spinal cord injury, which was induced by the application of 
vascular clips to the dura via a four-level T5 through T8 laminectomy. The degree of (a) 
spinal cord inflammation and tissue injury (histological score), (b) nitrotyrosine, (c) 
poly(adenosine diphosphate-ribose), (d) neutrophils infiltration, and (e) the activation of 
signal transducer and activator transcription 3 was markedly reduced in spinal cord tissue 
obtained from H. perforatum extract-treated mice. It could be demonstrated that H. 
perforatum extract significantly ameliorated the recovery of limb function.   
 
Froestl et al (2003) studied the effect of hyperforin on the processing of the amyloid precursor 
protein (APP) in rat pheochromocytoma PC12 cells, stably transfected with human wildtype 
APP. The authors observed transiently increased release of secretory APP fragments upon 
hyperforin treatment. Unique features, like a strong reduction of intracellular APP and the 
time course of soluble APP release, distinguished the effects of hyperforin from those of 
alkalizing agents and phorbol esters, well known activators of secretory processing of APP. 
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), a protonophore, induced an 
almost identical decrease in intracellular pH in PC12 cells as does hyperforin. Despite this, 
FCCP induced a less pronounced release of soluble APP fragments and only slightly reduced 
intracellular APP levels. These results suggest that hyperforin is an activator of secretory 
processing of APP. 
 
Silva et al (2004) assessed the neuroprotective role of a Hypericum perforatum ethanolic 
extract and obtained fractions in amyloid-beta peptide (Abeta)((25-35))-induced cell death in 
rat cultured hippocampal neurons. Lipid peroxidation was used as a marker of oxidative stress 
by following the formation of TBARS in rat cortical synaptosomes, after incubation with 
ascorbate/Fe2+, alone or in the presence of EC97 effective concentrations of H. perforatum 
fractions. Induced lipid peroxidation was significantly inhibited by fractions containing 
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flavonol glycosides, flavonol and biflavone aglycones, and by a fraction containing several 
phenols, mainly chlorogenic acid-type phenolics (21%, 77% and 98%, respectively). Lipid 
peroxidation evaluated after incubation with 25 µM Abeta(25-35), was significantly inhibited 
by H. perforatum extract. Cell viability was assessed by use of the Syto-13/PI assay. The total 
ethanolic extract (TE) and fractions containing flavonol glycosides, flavonol and biflavone 
aglycones, reduced Abeta(25-35)-induced cell death (65%, 58% and 59%, respectively). 
These results were further supported by morphological analysis of cells stained with cresyl 
violet. Peptide beta-amyloid(25-35) induced a decrease in cell volume, chromatin 
condensation and nuclear fragmentation, alterations not evident in the presence of the TE and 
fractions containing hypericins (hypericin concentration = 11.02 µM), or fractions containing 
flavonoids (quercetin concentration = 21.13 µM). Dendritic lesion, an evidence of 
neurodegeneration, was observed by neuronal staining with cobalt following insult with 
Abeta(25-35), but prevented after exposure to the peptide plus the fractions referred above. 
The results suggest that H. perforatum extracts may be endowed with neuroprotective 
compounds able to prevent Abeta(25-35)-induced toxicity.   
 
The major protein constituent of amyloid deposits in Alzheimer's disease (AD) is the amyloid 
beta-peptide (Abeta). Dinamarca et al (2006) have determined the effect of hyperforin on 
Abeta-induced spatial memory impairments and on Abeta neurotoxicity. Hyperforin decreases 
amyloid deposit formation in rats injected with amyloid fibrils in the hippocampus, decreases 
the neuropathological changes and behavioral impairments in a rat model of amyloidosis, and 
prevents Abeta-induced neurotoxicity in hippocampal neurons both from amyloid fibrils and 
Abeta oligomers, avoiding the increase in reactive oxidative species associated with amyloid 
toxicity. Both effects could be explained by the capacity of hyperforin to disaggregate 
amyloid deposits in a dose and time-dependent manner and to decrease Abeta aggregation and 
amyloid formation.  
 
Acute administration of Hypericum extract (4.0, 8.0, 12.0, and 25.0 mg/kg i.p.) in mice before 
retrieval testing increased the step-down latency during the test session. The same doses of 
Hypericum extract, on the other hand, failed to reverse scopolamine-induced amnesia of a 
two-trial passive avoidance task. Pretreatment of the animals with serotonergic 5-HT1A 
receptor antagonist (-)-pindolol (0.3, 1.0, and 3.0 mg/kg), serotonergic 5-HT2A receptor 
blocker spiperone (0.01, 0.03, and 0.1 mg/kg), alpha adrenoceptor antagonist phentolamine 
(1, 5, and 10 mg/kg), beta receptor antagonist propranolol (5, 7.5, and 10 mg/kg), 
dopaminergic D1 receptor antagonist SCH 23390 (0.01, 0.05, and 0.1 mg/kg), and 
dopaminergic D2 receptor antagonist sulpiride (5, 7.5, and 10 mg/kg) revealed the 
involvement of adrenergic and serotonergic 5-HT1A receptors in the facilitatory effect of 
Hypericum extract on retrieval memory. It is concluded that Hypericum extract may be a 
better alternative for treatment of depression commonly associated with dementia than other 
antidepressants known to have anticholinergic side effects causing delirium, sedation and 
even exacerbating already existing impaired cognition (Khalifa 2001).  
 
The effects of a Hypericum extract and hyperforin sodium salt were evaluated in rat and 
mouse avoidance tests by Klusa et al (2001). In a conditioned avoidance response (CAR) test 
on the rat, oral daily administration of hyperforin (1.25 mg/kg/day) or of the extract (50 
mg/kg/day) before the training sessions considerably improved learning ability from the 
second day onwards until the day 7. In addition, the memory of the learned responses 
acquired during 7 consecutive days of administration and training was largely retained even 
after 9 days without further treatment or training. The observations made using different doses 
indicate that these learning-facilitating and/or memory-consolidating effects by the agents 
follow inverse U-shaped dose-response curves in dose ranges lower than (for hyperforin) or 
equal to (for Hypericum extract) their effective dose in the behavioral despair test for 
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antidepressants. In a passive avoidance response test on the mouse, a single oral dose (1.25 
mg/kg) of hyperforin not only improved memory acquisition and consolidation, but also 
almost completely reversed scopolamine-induced amnesia. The single Hypericum extract 
dose tested (25 mg/kg) did not reveal any significant effects in the passive avoidance response 
(PAR) test on the mouse. These observations suggest that the Hypericum extract could be a 
novel type of antidepressant with memory enhancing properties, and indicate that hyperforin 
is involved in its cognitive effects. Pure hyperforin seems to be a more potent antidementia 
agent than an antidepressant. 
 
Kumar et al (2000, 2002) found that orally administered extracts of Hypericum perforatum of 
Indian origin (doses 100 mg and 200 mg /kg) to rats showed effects which could be 
interpreted as possible nootropic action. 
 
Widy-Tyszkiewicz et al (2002) investigated the effects of long-term Hypericum perforatum 
treatment on spatial learning and memory in rats. A hypericum powder (HP) standardized to 
0.3% hypericin content was administered orally for 9 weeks in doses of 4.3 and 13 µg/kg 
corresponding to therapeutic dosages in humans of 0.3 and 0.9 mg of total hypericins daily. A 
Morris water maze paradigm was used. The mean escape latency over 4 d for the Control 
group (21.9 s) and HP 4.3 group (21.7 s) was significantly greater than the latency of the HP 
13 group (15.8s). In the probe trial on day 5, the HP 13 group crossed the correct annulus in 
the SE quadrant more often (4.5) than the other groups: Con (2.4) and HP 4.3 (3.1). After 
completion of the behavioural experiment, the regional brain concentrations of monoamines 
and metabolites were estimated in selected brain regions, i.e. prefrontal cortex, hippocampus 
and hypothalamus. Significant differences in the content of monoamines and metabolites 
between the treatment groups compared to the control were detected. The increased 5-
hydroxytryptamine (5-HT) levels in the prefrontal cortex correlated positively with the 
retention of spatial memory. These findings show that the long-term administration of 
Hypericum perforatum can improve learning and spatial memory with significant changes in 
the content of monoamines in several brain regions. 
 
Administration of Hypericum perforatum (350 mg / kg daily for 21 days) significantly 
enhanced recall of passive avoidance behavior (PAB), but had no effect on the acquisition of 
conditioned avoidance responses (CARs). Rats stressed chronically (2 h daily for 21 days) 
displayed diminished recall of the PAB and this effect was abolished by St John's wort. 
Chronic administration of the "equivalent" to the stress dose of exogenous corticosterone (5 
mg / kg daily for 21 days) also impaired recall of PAB, and this effect was also reversed by 
Hypericum perforatum. None of the treatments produced significant motor coordination 
impairments as tested in a 'chimney' test. It appears that H. perforatum prevents stress-induced 
deterioration of memory in rats (Trofimiuk et al 2005, 2006). 
 
Mohanasundari et al (2006, 2007) tested the effect of an extract of Hypericum perforatum in 
chemically induced Parkinson’s disease in mice. Treatment with Hypericum perforatum 
extract resulted in an inhibition of monoamine oxidase-B activity and reduced astrocyte 
activation in striatal area. The effects were more pronounced when hypericum was combined 
with bromocriptine. 
 
Sanchez Reus et al (2007) designed a study to investigate the pro-oxidant activity of rotenone, 
the protective role of standardized extract of Hypericum perforatum (SHP), as well as the 
mRNA levels of antioxidant enzymes, in brain homogenates of rats following exposure to 
rotenone and SHP extract. Quercetin in liposomes, one active constituent, was tested in the 
same experimental conditions to serve as a positive control. The animals received 
- 28 - 
pretreatment with SHP (4 mg/kg) or quercetin liposomes (25 and 100 mg/kg) 60 min before 
of rotenone injection (2 mg/kg). All treatments were given intraperitoneally in a volume of 
0.5 ml/kg body weight, for 45 days. SHP extract exerted an antioxidant action which was 
related to a decrease of MnSOD activity and mRNA levels of some antioxidant enzymes 
evaluated. One possible mechanism of action of SHP extract may be related to quercetin in 
protecting neurons from oxidative damage. 
 
El-Sherbiny et al (2003) investigated the effect of acute administration of Hypericum 
perforatum extract (4.0, 8.0, 12.0, and 25.0 mg/kg ip) on the brain oxidative status of naive 
rats treated with an amnestic dose of scopolamine. The results showed that the administration 
of 1.4 mg/kg of scopolamine impaired the retrieval memory of rats. Pretreatment of the 
animals with Hypericum extract (4, 8, and 12 mg/kg) resulted in an antioxidant effect through 
altering brain malondialdehyde, glutathione peroxidase, and/or glutathione level/activity. 
 
 
I.2.1.1.5 Support in smoking cessation 
Catania et al (2003) investigated the effects of an extract of Hypericum perforatum (Ph-50) on 
withdrawal signs produced by nicotine abstinence in mice. Nicotine (2 mg/kg, four injections 
daily) was administered for 14 days to mice. Different doses of Ph-50 (125-500 mg/kg) were 
administered orally immediately after the last nicotine injection. In another experiment, Ph-50 
(500 mg/kg) was orally administered in combination with nicotine, i) starting from day 8 until 
the end of the nicotine treatment period, or ii) during nicotine treatment and after nicotine 
withdrawal, or iii) immediately after the last nicotine injection. The locomotor activity 
reduction induced by nicotine withdrawal was abolished by Ph-50, which also significantly 
and dose-dependently reduced the total nicotine abstinence score when injected after nicotine 
withdrawal.  
 
Mannucci et al (2007) investigated the possible involvement of 5-HT in the beneficial effects 
of H. perforatum on nicotine withdrawal signs. With the aim to induce nicotine dependence, 
nicotine (2 mg/kg, four intraperitoneal injections daily) was administered for 14 days to mice 
(NM). After nicotine withdrawal the measurement of 5-HT metabolism in the cortex showed 
a reduction of the 5-HT content while animals treated only with Hypericum extract showed a 
significant reduction of total abstinence score compared to controls. A selective 5-HT receptor 
antagonist inhibited the reduction of total abstinence score induced by H. perforatum. 
Moreover, 5-HT1A expression has been evaluated 30 days after nicotine withdrawal. The 
results show a significant increase of cortical 5-HT content in NM treated with H. perforatum, 
with a concomitant significant increase of 5-HT1A receptor.  
 
 
I.2.1.1.6 Treatment of alcoholism 
Several studies were performed in order to investigate the influence of hypericum extracts on 
alcohol intake in animals (Rezvani et al 1999, Perfumi et al 1999, Perfumi et al 2005, Perfumi 
et al 2005a, Coskun et al 2006). All studies report beneficial effects on ethanol withdrawal 
symptoms, additionally a reduction of alcohol intake in alcohol preferring animals was 
observed. Hypericum extracts and opioid receptor antagonists act synergistically (Perfumi et 
al 2003). 
 
The changes in the alcohol drinking behaviour may be caused by hyperforin (Perfumi et al 
2001, Wright et al 2003). In contrast, De Vry et al (1999) reported a reduction in alcohol 
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preference after administration of an extract with very low hyperforin content. Clinical data 
are missing (Uzbay 2008). 
 
 
I.2.1.1.7 Antibacterial activity 
Gibbons et al (2002) screened extracts of 34 species and varieties of the genus Hypericum for 
activity against a clinical isolate of methicillin-resistant Staphylococcus aureus, which in 
addition possessed a multidrug efflux mechanism conferring a high level of resistance to 
therapeutically useful antibiotics. Thirty-three of the 34 chloroform extracts showed 
significant activity in a disk diffusion assay, and five extracts had minimum inhibitory 
concentrations of 64 µg/ml.  
 
 
I.2.1.1.8 Antiinflammatory activity 
Schempp (2000) investigated the alloantigen presenting function of human epidermal cells 
(EC) exposed to Hypericum ointment in vivo in a mixed EC lymphocyte reaction (MECLR). 
The effect of Hypericum ointment was compared with the immunosuppressive effect of solar-
simulated radiation (SSR). Subsequently, the authors tested purified hyperforin in vivo and in 
vitro in a MECLR to evaluate its possible contribution to the effect of the Hypericum 
ointment. Furthermore, the effect of hyperforin on the proliferation of peripheral blood 
mononuclear cells (PBMC) in vitro was assessed. Compared with untreated skin, treatment 
with Hypericum ointment resulted in a significant suppression of the MECLR (P </= 0.001) 
that was similar to the effect of SSR. The combination of Hypericum ointment plus SSR was 
not significantly different from either treatment alone. EC isolated from skin treated with the 
hyperforin containing ointment also showed a reduced capacity to stimulate the proliferation 
of allogeneic T cells (P </= 0.001). Similarly, in vitro incubation of EC with hyperforin 
suppressed the proliferation of alloreactive T cells (P </= 0.001). Furthermore, hyperforin 
inhibited the proliferation of PBMC in a dose-dependent manner, without displaying 
pronounced toxic effects as determined by Trypan blue staining. The results demonstrate an 
inhibitory effect of Hypericum extract and of its metabolite hyperforin on the MECLR and on 
the proliferation of T lymphocytes that may provide a rationale for the traditional treatment of 
inflammatory skin disorders with Hypericum extracts.   
 
Three preparations of Hypericum perforatum L. (a hydroalcoholic extract, a lipophilic extract 
and an ethylacetic fraction) and the pure compounds hypericin, adhyperforin, amentoflavone, 
hyperoside, isoquercitrin, hyperforin dicyclohexylammonium (DHCA) salt and 
dicyclohexylamine were evaluated for their topical anti-inflammatory activity (Sosa et al 
2007). H. perforatum preparations provoked a dose-dependent reduction of Croton-oil-
induced ear oedema in mice, showing the following rank order of activity: lipophilic extract > 
ethylacetic fraction > hydroalcoholic extract (ID50 220, 267 and >1000 microg cm-2, 
respectively). Amentoflavone (ID50 0.16 micromol cm-2), hypericin (ID50 0.25 micromol cm-
2), hyperforin DHCA salt (ID50 0.25 micromol cm-2) and adhyperofrin (ID50 0.30 micromol 
cm-2) had anti-inflammatory activity that was more potent or comparable to that of 
indometacin (ID50 0.26 micromol cm-2), whereas isoquercitrin and hyperoside were less 
active (ID50 about 1 micromol cm-2). As dicyclohexylamine alone was inactive, the effect of 
hyperforin DHCA salt can be attributed completely to the phloroglucinol moiety. The 
pharmacological activity and phytochemical profile of the tested extracts and fraction suggest 
that different constituents are involved in the topical antiphlogistic property of H. perforatum 
in-vivo.   
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Eckert et al (2001) tested the effects of hyperforin on the fluidity of crude brain membranes 
from young guinea pigs. Hyperforin modifies specific membrane structures in different ways. 
It decreases the flexibility of fatty acids in the membrane hydrocarbon core, but fluidizes the 
hydrophilic region of membrane phospholipids. Relatively low concentrations of hyperforin 
(0.3 µmol/l) significantly decreased the annular fluidity of lipids close to membrane proteins. 
These findings are remarkable, as inhibition of several neurotransmitter-uptake systems and 
modulation of several ionic conductance mechanisms by hyperforin occur in the same 
concentration range. However, bulk fluidity was unchanged by this low hyperforin 
concentration. The results emphasise a physicochemical interaction of hyperforin with 
specific membrane structures that probably contribute to its pharmacological properties.   
 
 
I.2.1.1.9 Wound healing 
The wound-healing effect of St. John's Wort (Hypericum perforatum L.) extract was 
evaluated by comparing with dexpanthenol and titrated extract of Centella asiatica (TECA) on 
cultured chicken embryonic fibroblasts (Ozturk et al 2006). Chicken embryonic fibroblasts 
from fertilized eggs were incubated with the plant extract, dexpanthenol and TECA. The 
wound-healing activity of Hypericum perforatum extract seems to be mainly due to the 
increase in the stimulation of fibroblast collagen production and the activation of fibroblast 
cells in polygonal shape, which plays a role in wound repair by closing damaged area. The 
findings demonstrated the wound-healing activity of Hypericum perforatum, which has 
previously been based on ethnomedical data. 
 
 
I.2.1.1.10 Pregnancy, lactation 
Rayburn et al (2001) investigated the cognitive impact of prenatal exposure to hypericum in 
CD-1 mice. Hypericum (182 mg/kg/day) or a placebo was consumed in food bars for 2 weeks 
before mating and throughout gestation. The hypericin content in the hypericum formulation 
was in the middle range of standardized hypericum products. One offspring per gender from 
each litter (hypericum 13, placebo 12) was tested on each of the following tasks: juvenile 
runway with adult memory, adult Morris maze, adult passive avoidance, or adult straight 
water runway followed by a dry Cincinnati maze. Learning occurred in both genders in all 
tasks (P<.003) with no significant differences between treatments at the final trial. Female 
offspring exposed to hypericum, rather than to a placebo, required more time to learn the 
Morris maze task (P<.05). Postlearning sessions did not show any significant differences. In 
conclusion, prenatal exposure to a therapeutic dose of hypericum did not have a major impact 
on certain cognitive tasks in mice offspring.  
 
 
I.2.1.1.11 Photodynamic therapy 
Hypericin is considered as potential agent in the photodynamic therapy of cancer (Agostinis 
et al 2002). However, since only isolated hypericin and not extracts have been tested this 
approach is out of the scope of this assessment. 
 
 
I.2.1.1.12 Other effects 
Capasso et al (2005) evaluated the effect of hypericum on rat and human vas deferens 
contractility. Hypericum extract (1 to 300 microM) decreased in a concentration dependent 
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manner the amplitude of electrical field stimulation and agonist induced contractions with the 
same potency, suggesting direct inhibition of rat vas deferens smooth muscle. Of the chemical 
constituents of Hypericum extract tested hyperforin but not hypericin or the flavonoids 
quercitrin, rutin and kaempferol inhibited phenylephrine induced contractions. Hypericum 
extract and hyperforin also inhibited phenylephrine induced contractions in human vas 
deferens. These results might explain delayed ejaculation described in patients receiving 
Hypericum extract. 
 
Effects of different extracts of Hypericum perforatum L. on the kindling epileptic discharges 
were analyzed by Ivetic et al (2002). The experiment was carried out on Chinchilla rabbits 
with chronically implanted electrodes in cortical structures and hippocampus. Water, n-
butanol and ether fractions (mass concentrations 0.1 g/ml) of crude ethanol extract of 
Hypericum perforatum were used. The particular extracts were given intramuscularly in 
single dose of 1 ml/kg BW. The bioelectric activity was registered before and after 
applications of each extracts. The obtained results show that the effect depends on the 
constituents present in particular fractions. Most polar constituents that remained in water 
fraction exerted highest antiepileptic activity in all (100%) animals tested. Substances present 
in butanol fraction repressed the epileptic manifestations in 40% of animals with kindling 
epilepsy, whereas lipid-soluble constituents in ether fraction potentiated the epileptic activity. 
 
Hypericin, pseudohypericin and hyperforin at doses as low as 2.5 µmol/l are potent 
antioxidants in the LDL oxidation systems used. These results indicate that these derivatives 
have possible antiatherogenic potential (Laggner et al 2007). An extract rich in flavonoids 
lowered serum levels of total cholesterol, total triglycerides and LDL (Zou et al 2005). 
 
Free radical scavenging and antioxidant activities of a standardized extract of Hypericum 
perforatum were examined for inhibition of lipid peroxidation, for hydroxyl radical 
scavenging activity and interaction with 1,1-diphenyl-2-picrylhydrazyl stable free radical 
(DPPH) by Benedi et al (2004). The results suggest that hypericum extracts shows relevant 
antioxidant activity both in vitro and in a cell system, by means of inhibiting free radical 
generation and lipid peroxidation. 
 
Antioxidative and radical scavenging effects are also reported for the flavonoid fraction of 
Hypericum perforatum (Zou et al 2004) and for several commercially available formulations 
(Hunt et al 2001). The antioxidative properties protect human neuroblastoma cells against 
induced apoptosis (Jang et al 2002). 
 
Genovese et al (2006) evaluated the effect of Hypericum perforatum extract on acute 
pancreatitis induced by cerulein administration in male CD mice. The degree of pancreatic 
inflammation and tissue injury (histological score), expression of ICAM-1, the staining for 
nitrotyrosine and PAR, and myeloperoxidase activity was markedly reduced in pancreatic 
tissue sections obtained from cerulein-treated mice administered Hypericum perforatum 
extract (30 mg/kg, suspended in 0.2 mL of saline solution, o.s.). Moreover, the treatment with 
Hypericum perforatum extract significantly reduced the mortality rate at 5 days after cerulein 
administration.  
 
Following the traditional use of Hypericum against viruses of the Herpes family in Greece 
Axarlis et al (1998) found antiviral activity of a methanolic extract against Human 
Cytomegalovirus.  
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Panossian et al (1996) concluded that the antiviral, antiinflammatory and antitumroal effects 
of hypericin may result from the inhibition of the PKC-mediated signalling pathway 
demonstrated in human leukocytes, which influences the arachidonic acid metabolism and the 
interleukin-1-alpha production resulting in an immunosuppressive effect. 
 
I.2.1.2 Assessor’s overall conclusions on pharmacology 
There are numerous pharmacological findings published which propose a similar 
pharmacology to established synthetic antidepressant drugs. However, the discussion on the 
responsible compounds in the extract is still ongoing. Since several hydroethanolic and 
hydromethanolic extracts with different contents of hypericin and hyperforin are positively 
tested it could be concluded that the naphthodianthrones and the phloroglucine derivatives are 
of minor relevance for the antidepressant activity. 
 
 
I.2.2 Pharmacokinetics 
I.2.2.1 Overview of available data regarding the herbal substance(s), herbal preparation(s) 
and relevant constituents thereof 
Wurglics et al (2006) published a review on pharmacokinetic data of compounds of 
hypericum extracts. The hyperforin plasma concentration in humans was investigated in a 
small number of studies. The results of these studies indicate a relevant plasma concentration, 
comparable with that used in in-vitro tests. Furthermore, hyperforin is the only ingredient of 
H. perforatum that could be determined in the brain of rodents after oral administration of 
alcoholic extracts. The plasma concentrations of the hypericins were, compared with 
hyperforin, only one-tenth and, until now, the hypericins could not be found in the brain after 
oral administration of alcoholic H. perforatum extracts or pure hypericin.  
 
The intestinal absorption characteristics of protohypericin were studied and compared with 
those of hypericin by Kamuhab et al (1999). The Caco-2 model was used as a model of the 
intestinal mucosa to assess transepithelial transport and cell uptake. Following application of 
the individual compounds (80-200 microM) to the apical side of the monolayers, the 
appearance in the basolateral compartment was found to be very low (<0.5%/5 h), but was 
comparable for both compounds. A lag-time of 2-3 h was observed, suggesting gradual 
saturation of binding sites on the membrane or inside the cells. Uptake experiments of 
protohypericin and hypericin by Caco-2 cells revealed a very significant cellular accumulation 
(4-8%); uptake was characterised by saturation after 3 h. The findings of this study suggest 
that protohypericin has comparable absorption characteristics as hypericin. 
 
Investigations by Sattler et al (1997) indicate that a significant accumulation of hypericin in 
the cell membrane and the cell nucleus membrane of Caco-2-cells takes place. The authors 
conclude that hypericin is absorbed through the intestinal epithelium by passive transcellular 
diffusion and that increasing its solubility by cyclodextrin appears as a promising approach to 
increase its oral bioavailability for pharmaceutical formulations. 
 
Plasma levels of hypericin in rats in the presence and absence of procyanidin B2 or 
hyperoside were determined by reversed phase HPLC using fluorimetric detection 
(Butterweck et al 2003). Both compounds increased the oral bioavailability of hypericin by 
ca. 58 % (B2) and 34 % (hyperoside). Procyanidin B2 and hyperoside had a different 
influence on the plasma kinetics of hypericin; median maximal plasma levels of hypericin 
were detected after 360 min (C max : 8.6 ng/mL) for B2, and after 150 min (C max : 8.8 
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ng/mL) for hyperoside. It can be speculated that, when administered together with these 
compounds, a significant accumulation of hypericin in rat plasma in the presence of both 
polyphenols might be responsible for the observed increased in vivo activity. 
 
Juergenliemk et al (2003) examined the pathway of miquelianin (quercetin 3-O-beta-D-
glucuronopyranoside), a flavonoid with antidepressant acitivity, from the small intestine to 
the central nervous system. The permeability coefficient of miquelianin (Pc = 0.4 +/- 0.19 x 
10(-6) cm/sec) was in the range of orally available drugs assuming sufficient absorption from 
the small intestine. The permeability coefficients (blood-brain-barrier: Pc = 1.34 +/- 0.05 x 
10(-6) cm/sec; blood-CSF-barrier: Pc = 2.0 +/- 0.33 x 10(-6) cm/sec) indicate the ability of 
miquelianin to cross both barriers to finally reach the CNS. 
 
Paulke et al (2008) suggested that not the genuine flavonoid glycosides reach the plasma. 
After oral uptake they are deglycosylated in the small intestine, after absorption the quercetin 
aglycone is glucuronidated (yielding e.g. miquelianin). Further methylation is possibly 
leading to isorhamnetin and tamarixetin. These metabolites have the ability to penetrate the 
blood-brain-barrier. Moreover, a significant accumulation of these metabolites in the CNS 
tissue is observed. After a single dose of a hypericum extract (1600 mg/kg rat) the quercetin 
plasma level increased rapidly and reached the maximum of about 700 ng/ml after 4 hours. 
After 24 hours, 50% of the Cmax was still measurable. In contrast the concentration level of 
isorhamnetin/Tamarixetin increase much slower, the maximum was reached after 24 hours 
with a Cmax of 903 ng/ml. Repeated doses of 1600 mg/kg rat yielded a continuous increase in 
the plasma levels of quercetin and isorhamnetin for 5 days, after that time the concentration 
ermained constant. 
 
 
I.2.2.2 Assessor’s overall conclusions on pharmacokinetics 
The few data on pharmacokinetics do not allow a final conclusion about absorption, 
distribution, metabolism and excretion of constituents. Additionally it is not clear whether 
putative active constituents of hypericum extracts reach the brain tissue in sufficient 
concentration. 
 
 
 
I.2.3 Toxicology 
I.2.3.1 Overview of available data regarding the herbal substance(s)/herbal preparation(s) 
and constituents thereof 
I.2.3.1.1 Single-dose toxicity 
For a methanolic extract (DER 3-6:1) the following data are published in the SPC: 
Species Application LD50 (mg / kg BW) 
Mouse oral ≥ 5000 
Rat oral ≥ 5000 
Mouse intraperitoneal 1780 
Rat intraperitoneal 1000 
 
Intravenous application of hypericin was well tolerated by rhesus monkeys in a dose of 2 mg / 
kg, at 5 mg/kg transient severe photosensitivity rash occurred (Fox et al 2001). The amount of 
hypericin administered daily in usual therapeutic dosages is not more than 3 mg for adults (= 
0.04 mg / kg). 
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I.2.3.1.2 Repeated-dose toxicity 
Studies on long-term toxicity (900 mg/kg and 2700 mg/kg extract per day (LI 160), 26 weeks 
treatment) in rats and dogs revealed only minor non-specific symptoms (weight loss, minor 
pathological changes in liver and kidney). All changes reverted to normal when treatment was 
stopped (Leuschner 1996, Greeson et al 2001). The dosages were approximately 70 and 200 
times the mean therapeutic dosage. Therefore the therapeutic dosage of 13 mg/kg per day (= 
900 mg extract) can be regarded as safe from that perspective. 
 
I.2.3.1.3 Mutagenicity 
The genotoxicity testing of ethanolic extracts showed weak positive results in the AMES-test 
(Salmonella typhimurium TA 98 and TA 100, with and without metabolic activation). After 
chromatographic separation the effect could be assigned to quercetin (Poginsky et al 1988, 
Schimmer 1988). 
Okpanyi et al (1990) tested an ethanolic extract (DER 1:5-7, 0.2-0.3% hypericin, 0.35 mg/g 
quercetin) in several in-vivo (mammalian spot test in mice, chromosome aberration test in 
Chinese hamsters) and in-vitro test systems (HGPRT hypoxanthine-guanine-phosphoribosyl-
transferase etst, UDS unscheduled DNA synthesis test, cell transformation test). The authors 
could not detect signs of a mutagenic potential of the extract. 
 
I.2.3.1.4 Carcinogenicity 
No data available 
 
I.2.3.1.5 Phototoxicity 
In order to estimate the potential risk of phototoxic skin damage during antidepressive 
therapy, Bernd et al (1999) investigated the phototoxic activity of hypericin extract using 
cultures of human keratinocytes and compared it with the effect of the well-known phototoxic 
agent psoralen. The absorbance spectrum of the Hypericum extract revealed maxima in the 
whole UV range and in parts of the visible range. Human keratinocytes were cultivated in the 
presence of different Hypericum concentrations. The determination of the bromodeoxyuridine 
incorporation rate showed a concentration- and light-dependent decrease in DNA synthesis 
with high hypericin concentrations (≥ 50 µg/mL) combined with UVA or visible light 
radiation. In the case of UVB irradiation a clear phototoxic cell reaction was not detected. The 
authors found phototoxic effects even with 10 ng/mL psoralen using UVA with the same 
study design as in the case of the Hypericum extract. These results confirm the phototoxic 
activity of Hypericum extract on human keratinocytes. However, the blood levels that are to 
be expected during antidepressive therapy are presumably too low to induce phototoxic skin 
reactions.   
 
Schempp et al (2002) assessed the phototoxic and apoptosis-inducing capacity of 
pseudohypericin (PH) compared to hypericin (H) in a cell culture model with human 
leukemic lymphoma cells (Jurkat). Treatment with both photoactivated H and PH resulted in a 
dose-dependent inhibition of cell proliferation, whereas not photoactivated H and PH had no 
effect at the concentrations tested. The half-maximal inhibitory concentration (IC50) of H was 
lower (100 ng/mL) as compared to PH (200 ng/mL) (p < 0.05). In an apoptosis assay the 
authors found a dose-dependent increase of DNA fragmentation after treatment with both 
photoactivated H and PH. The cytotoxic potential of PH should be taken into account during 
systemic therapy with Hypericum extracts, since PH is about two times more abundant than H 
in Hypericum perforatum. 
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Wilhelm et al (2001) investigated the phototoxic potential of 3 Hypericum perforatum 
extracts from different sources as well as some of its main constituents. Hypericum 
perforatum extracts demonstrated cytotoxicity and photocytotoxicity in a dose and UVA-dose 
dependent manner. Hypericine itself also evoked severe phototoxic effects and was thus 
identified as the main phototoxic constituent. Among the tested flavonoids quercitrin was 
found to be cytotoxic, while rutin unexpectedly demonstrated phototoxicity whereas 
quercitrin was effective to control the phototoxic activity of Hypericum perforatum extracts. 
 
Clinical evidence suggests that administration of Hypericum perforatum (Hp) extracts 
containing the photo-activated hypericin compounds may cause fewer skin photosensitization 
reactions than administration of pure hypericin. Schmitt et al (2006) conducted a study to 
determine whether the phototoxicity of hypericin in HaCaT keratinocytes could be attenuated 
by H. perforatum extracts and constituents. Two extracts, when supplemented with 20 
microM hypericin: (1) an ethanol re-extraction of residue following a chloroform extraction 
(denoted ethanol(-chloroform)) (3.35 microM hypericin and 124.0 microM total flavonoids); 
and (2) a chloroform extract (hypericin and flavonoids not detected), showed 25% and 50% 
(p<0.0001) less phototoxicity than 20 microM hypericin alone. Two H. perforatum 
constituents, when supplemented with 20 microM hypericin: (1) 10 microM chlorogenic acid; 
and (2) 0.25 microM pyropheophorbide, exhibited 24% (p<0.05) and 40% (p<0.05) less 
phototoxicity than 20 microM hypericin alone. The peroxidation of arachidonic acid was 
assessed as a measure of oxidative damage by photo-activated hypericin, but this parameter of 
lipid peroxidation was not influenced by the extracts or constituents. However alpha-
tocopherol, a known antioxidant also did not influence the amount of lipid peroxidation 
induced in this system. These observations indicate that hypericin combined with H. 
perforatum extracts or constituents may exert less phototoxicity than pure hypericin, but 
possibly not through a reduction in arachidonic acid peroxidation.   
 
Schmitt et al (2006a) examined the cytotoxicity of Hp extracts prepared in solvents ranging in 
polarity, fractions of one extract, and purified compounds in three cell lines. All extracts 
exhibited significant cytotoxicity; those prepared in ethanol (no hyperforin, 3.6 microM 
hypericin, and 134.6 microM flavonoids) showed between 7.7 and 77.4% cell survival (p < 
0.0001 and 0.01), whereas the chloroform and hexane extracts (hyperforin, hypericin, and 
flavonoids not detected) showed approximately 9.0 (p < 0.0001) and 4.0% (p < 0.0001) 
survival. Light-sensitive toxicity was observed primarily with the ethanol extracts 
sequentially extracted following removal of material extracted in either chloroform or hexane. 
The absence of light-sensitive toxicity with the Hp extracts suggests that the hypericins were 
not playing a prominent role in the toxicity of the extracts.   
 
A study of Traynor et al (2005) used HaCaT keratinocytes to investigate the photoclastogenic 
ability of hypericin on irradiation with UVA. The results show that although the combination 
of hypericin and UVA light increased the genotoxic burden, when all factors are taken into 
account, the risk of significant photogenotoxic damage incurred by the combination of 
Hypericum extracts and UVA phototherapy may be low in the majority of individuals. 
 
Phototoxicity to the eye 
To determine if hypercin could be phototoxic to the eye, He et al (2004) exposed human lens 
epithelial cells to 0.1-10 microM hypericin and irradiated them with 4 J/cm2 UV-A or 0.9 
J/cm2 visible light. Neither hypericin exposure alone nor light exposure alone reduced cell 
viability. In contrast, cells exposed to hypericin in combination with UV-A or visible light 
underwent necrosis and apoptosis. The ocular antioxidants lutein and N-acetyl cysteine did 
- 36 - 
not prevent damage. Thus, ingested Hypericum extract is potentially phototoxic to the eye and 
could contribute to early cataractogenesis.  
 
Lens alpha-crystallin, isolated from calf lenses, was irradiated in the presence of hypericin (5 
x 10(-5) M, 10 mM ammonium bicarbonate, pH 7.0) and in the presence and absence of light 
(> 300 nm, 24 mW/cm2). Hypericin-induced photosensitized photopolymerization as assessed 
by sodium dodecylsulfate-polyacrylamide gel electrophoresis. Further analysis of the 
oxidative changes occurring in alpha-crystallin using mass spectrometry showed specific 
oxidation of methionine, tryptophan and histidine residues, which increased with irradiation 
time. Hypericin did not damage the lens protein in the dark. Damage to alpha-crystallin could 
undermine the integrity of the lens directly by protein denaturation and indirectly by 
disturbing chaperone function. Therefore, in the presence of light, hypericin can induce 
changes in lens protein that could lead to the formation of cataracts. The authors conclude that 
appropriate precautions should be taken to protect the eye from intense sunlight while on this 
antidepressant medication (Schey et al 2000). 
 
Wahlman et al (2003) found that the total accumulated protein leakage was positively 
correlated (r = 0.9) with variability in focal length. Lenses treated with hypericin and 
irradiated with UVB had an increase in focal length variability as compared with the lenses 
that were only UVB-irradiated. Lenses without UVB irradiation had much lower focal length 
variability than irradiated lenses. For non-hypericin-treated lenses, UVB-irradiated lenses had 
a larger variability (4.58 mm) than the unirradiated lenses (1.78 mm). The lenses incubated in 
elevated glucose concentrations had a focal length variability (3.23 mm) equivalent to that of 
the unirradiated hypericin-treated lenses (3.54 mm). The authors conclude that photooxidative 
damage by hypericin results in changes in the optical properties of the lens, protein leakage 
and finally cataract formation. In contrast to this, high concentrations of glucose induced 
protein leakage but not changes in optical properties or the opacity associated with a cataract. 
This work provides further evidence that people should protect their eyes from intense 
sunlight when taking St. John's Wort.   
 
To determine if hypericin might be phototoxic to the human retina, Wielgus et al (2006) 
exposed human retinal epithelial cells to 10(-7) to 10(-5) M hypericin. Fluorescence emission 
detected from the cells (lambda(exc) = 488 nm; lambda(em) = 505 nm) confirmed hypericin 
uptake by human RPE. Neither hypericin exposure alone nor visible light exposure alone 
reduced cell viability. However when irradiated with 0.7 J/cm(2) of visible light (lambda > 
400 nm) there was loss of cell viability as measured by MTS and LDH assays. The presence 
of hypericin in irradiated hRPE cells significantly changed the redox equilibrium of 
glutathione and a decrease in the activity of glutathione reductase. Increased lipid 
peroxidation as measured by the TBARS assay correlated to hypericin concentration in hRPE 
cells and visible light radiation. Thus, ingested Hypericum extract is potentially phototoxic to 
retina and could contribute to retinal or early macular degeneration. 
 
I.2.3.1.6 Reproduction Toxicity 
Ondrizek et al (1999) incubated zona-free hamster oocytes for 1 hour in St. John's wort 
(Hypericum perforatum), or control medium before sperm-oocyte interaction. The DNA of 
herb-treated sperm was analyzed with denaturing gradient gel electrophoresis. Pre-treatment 
of oocytes with 0.6 mg/mL of St. John's wort resulted in zero penetration. A lower 
concentration (0.06 mg/mL) had no effect. Exposure of sperm to St. John's wort resulted in 
DNA denaturation. Sperm exposed to 0.6 mg/mL of St. John's wort showed mutation of the 
BRCA1 exon 11 gene. The data suggested in the view of the authors that St. John's wort at 
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high concentrations damage reproductive cells. St. John's wort was mutagenic to sperm cells. 
Since the concentrations used were several orders of magnitude higher than considered as 
therapeutically relevant these effects should be considered with caution (Greeson et al 2001). 
 
Rayburn et al (2001) examined the influence of 180 mg / kg daily of a hypericum extract on 
long-term growth and physical maturation of mouse offspring for 2 weeks before conception 
and throughout gestation. No differences between the hypericum group and the placebo group 
could be detected. 
 
Assessor’s comment: 
Details on the type of extract are missing. 
 
The purpose of a study of Gregoretti et al (2004) was to investigate the effects of a treatment 
with hypericum administered prenatally and during breastfeeding (from 2 weeks before 
mating to 21 days after delivery) in Wistar rats. Two doses of the extract were chosen, 100 
mg/kg per day, which, based on surface area, is comparable to the dose administered to 
humans, and 1000 mg/kg per day. A microscopical analysis of livers, kidneys, hearts, lungs, 
brains, and small bowels was performed. A severe damage was observed in the livers and 
kidneys of animals euthanized postnatally on days 0 and 21. The lesions were more severe 
with the higher dose and in animals that were breastfed for 21 days; however, an important 
renal and hepatic damage was evident also with the dose of 100 mg/kg per day. In addition, 
similar serious hepatic and renal lesions were evident also in animals that were exposed to 
hypericum only during breastfeeding. In particular, a focal hepatic damage, with 
vacuolization, lobular fibrosis, and disorganization of hepatic arrays was evident; in the 
kidney, a reduction in glomerular size, disappearance of Bowman's space, and hyaline tubular 
degeneration were found. The results obtained in this study indicate that further, appropriate 
histological studies should be performed in other animal species to better evaluate the safety 
of hypericum extracts taken during pregnancy and breastfeeding.   
 
Borges et al (2005) treated inseminated rats orally with a methanilc extract of Hypericum 
perforatum. A dosage of 36 mg/kg was given on days 9-15 of pregnancy (= period of 
organogensis). No clinical signs of maternal toxicity were found. In the administered dose 
Hypericum extract did not interfere with the progress of gestation during organogenesis in 
rats. 
 
 
I.2.3.2 Assessor’s overall conclusions on toxicology 
The few data available on acute and subchronic toxicity do not reveal signs of a risk to the 
patient. The weak positive outcome of tests on mutagenicity of ethanolic extracts is explained 
with the presence of quercetin in the extracts. Tests on reproduction toxicity demonstrated no 
differences between Hypericum extract (108 mg/kg) and placebo in mice. Numerous 
publications deal with the potential phototoxicity of hypericin and Hypericum extracts. 
Extracts exert less phototoxicity than pure hypericin. Considering the outcome of clinical test 
on phototoxicity herbal preparations of Hypericum perforatum can be considered as safe 
when administered in the proposed dosage. The data on reproduction toxicology are 
contradictory. For safety reasons the oral use of Hypericum during pregnancy and lactation 
should not be recommended. 
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I.3 CLINICAL DATA 
I.3.1 Clinical Pharmacology  
I.3.1.1 Pharmacodynamics 
I.3.1.1.1 Overview of available data regarding the herbal substance(s)/herbal preparation(s) 
including data on constituents with known therapeutic activity. 
I.3.1.1.2 Assessor’s overall conclusions on Pharmacodynamics 
To be completed 
I.3.1.2 Pharmacokinetics 
I.3.1.2.1 Overview of available data regarding the herbal substance(s)/herbal preparation(s) 
including data on constituents with known therapeutic activity.  
Biber et al (1998) investigated the pharmacokinetics of hyperforin after oral administration of 
300, 600 and 1200 mg of two different ethanolic extracts (5% and 0.5% hyperforin). 
Maximum plasma levels of hyperforin were reached after 2.8 to 3.6 hours. The 5% extract 
yielded a total AUC0-∞ of 1336, 2215 and 3378 h x ng/ml. The hyperforin pharmacokinetics 
were linear up to 600 mg of the extract, higher dosages resulted in a lower concentration than 
linear extrapolation would expect. The plasma concentrations of hyperforin after 
administration of the other extract were considerably lower. In a repeated dose study no 
accumulation of hyperforin could be detected, the steady state plasma concentration after 3 x 
300 mg/day of the extract was approximately 100 ng/ml. 
 
The objective of two open phase I clinical trials (Schulz et al 2005) was to obtain 
pharmacokinetic data of hypericins, hyperforin and flavonoids from a hypericum extract 
containing tablet. Each trial included 18 healthy male volunteers who received the test 
preparation, containing 900 mg dry extract of St John's wort (STW 3-VI, Laif 900), either as a 
single oral dose or as a multiple once daily dose over a period of 14 days. After single dose 
intake, the key pharmacokinetic parameters were determined as follows: Hypericin: Area 
under the curve (AUC(0-infinity)) = 78.33 h x ng/ml, maximum plasma concentration (Cmax) 
= 3.8 ng/ml, time to reach Cmax (tmax) = 7.9 h, and elimination half-life (t1/2) = 18.71 h; 
pseudohypericin: AUC(0-infinity) = 97.28 h x ng/ml, Cmax = 10.2 ng/ml, tmax = 2.7 h, t1/2 
= 17.19 h; hyperforin: AUC(0-infinity) = 1550.4 h x ng/ml, Cmax = 122.0 ng/ml, tmax = 4.5 
h, t1/2 = 17.47 h. Quercetin and isorhamnetin showed two peaks of maximum plasma 
concentration separated by about 3-3.5 h. Quercetin: AUC(0-infinity) = 417.38 h x ng/ml, 
Cmax (1) = 89.5 ng/ml, tmax (1) = 1.0 h, Cma (2) = 79.1 ng/ml, tmax (2) = 4.4 h, t1/2 = 2.6 h; 
isorhamnetin: AUC(0-infinity) = 155.72 h x ng/ml, Cmax (1) = 12.5 ng/ml, tmax (1) = 1.4 h, 
Cmax (2) = 14.6 ng/ml, tmax (2) = 4.5 h, t1/2 = 5.61 h. Under steady state conditions reached 
during multiple dose administration similar results were obtained.  
 
A study from Johne et al (2004) evaluated the influence of cimetidine and carbamazepine on 
the pharmacokinetics of hypericin and pseudohypericin. In a placebo-controlled, double blind 
study, 33 healthy volunteers were randomized into three treatment groups that received 
Hypericum extract extract (LI160) with different comedications (placebo, cimetidine, and 
carbamazepine) for 7 days after a run-in period of 11 days with Hypericum extract alone. 
Hypericin and pseudohypericin pharmacokinetics were measured on days 10 and 17. 
Between-group comparisons showed no statistically significant differences in AUC(0-24), 
C(max), and t(max) values for hypericin and pseudohypericin. Within-group comparisons, 
however, revealed a statistically significant increase in hypericin AUC(0-24) from a median 
of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine 
comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-
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102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine 
comedication compared to the baseline pharmacokinetics in each group. Hypericin and 
pseudohypericin pharmacokinetics were only marginally influenced by comedication with the 
enzyme inhibitors and inducers cimetidine and carbamazepine.   
 
 
I.3.1.2.2 Assessor’s overall conclusions on pharmacokinetics 
Pharmacokinetic data on the most compounds which are considered to contribute to the 
activity are available. The long elimination lalf-life has to be considered after overdose. The 
possible role of metabolites is not addressed yet. 
 
 
I.3.2 Clinical Efficacy4  
I.3.2.1 Dose response studies 
I.3.2.2 Clinical studies (case studies and clinical trials) 
I.3.2.2.1 Studies on the treatment of depression 
 
Extract LI 160 
 
Extract LI 160 
Extraction 
solvent 
80 % methanol 
DER 3-6:1, initially 4-7:1 
Hypericin 0,12-0,28 % 
Hyperforin App. 4.5% (Mueller et al 2006) 
Flavonoids App. 8.3% (Mueller et al 2006) 
 
From several notes in publications it can be assumed that the content of hyperforin is in the 
range 3-6%. 
 
Study Bjerkenstedt et al 2005 
Indication mild to moderate major Depression (DSM-IV: 296.31, 296.32); 
minimum of a total score of 21 on the 21-item Hamilton 
Depression scale 
Duration of use 4 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
20 mg fluoxetine 
multicentre n=15 
Studydesign 
number of patients 163 
Outcome HAMD reduction: 
                                                 
4 In case of traditional use the long-standing use and experience should be assessed. 
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LI 160: from 24.9±4.5 to 15.0±8.4 (-9.9±8.1)  
Fluoxetine: from 23.8±3.7 to 14.9±8.4 (-8.9±8.0) 
Placebo: from 25.2±4.6 to 15.5±6.7 (-9.7±7.0) 
 
Conclusion: LI 160 and fluoxetine are not more effective in 
short-term treatment in mild to moderate depression than 
placebo. 
Hypericum is better tolerated than fluoxetine 
Comment Short time of treatment; high number of drop-outs in all groups 
(Hypericum start n=59, end n=38; fluoxetine start n=57, end 
n=37; placebo start n=58, end n=40) 
 
Study Fava et al 2005  
Indication major depressive disorder (HAMD-17 ≥ 16) 
Duration of use 12 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
20 mg/d fluoxetine 
multicentre n=2 
Studydesign 
number of patients 135 
Outcome HAMD reduction (ITT-analysis): 
LI 160: -38 %, from 19.6± 3.5 to 10.2 ± 6.6 
Fluoxetine: -30 %, from 19.6 ± 3.1 to 13.3 ± 7.3 
Placebo: -21 %, from 19.9 ± 2.9 to 12.6 ± 6.4 
 
Conclusion: LI 160 is significantly more effective than fluoxetine 
and superior to placebo. It is well tolerated and safe. 
Comment Sample smaller than originally planned; the lack of efficacy of 
fluoxetine is explained by the fixed-dose approach. 
 
Study Brenner et al 2000 
Indication mild to moderate depression (HAMD: ≥ 17, according to DSM 
IV) 
Duration of use 7 weeks 
Daily dosage 600 mg (1st week) 
900 mg (6 weeks) 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no? 
reference-
controlled 
50 mg sertraline (1st week) 
75 mg sertraline (6 weeks) 
multicentre no 
Studydesign 
number of patients 30 
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Outcome HAMD reduction:  
LI 160: -40 % ± 30 %; from 21.3 ± 3.2 to 12.7 ± 6.7) 
Sertraline: -42 % ± 24 %, from 21.7 ± 2.7 to 12.5 ± 5.6) 
 
Conclusion: 
LI 160 is as effective as sertraline in the treatment of mild to 
moderate depression. 
Comment Small number of patients, relatively high drop out rate. 
In the chapter ‘Study medication’ placebos are mentioned. 
However, no placebo group in table of results. 
 
Study HDTSG 2002 
Indication moderately severe major depressive disorder (according to DSM-
IV; HAM-D ≥ 20; GAF ≤ 60) 
Duration of use 8 weeks 
Daily dosage 900-1800 mg (3 x 300- 3 x 600 mg) 
Single dosage 300 – 600 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
50-150 mg sertraline 
multicentre n=12 
Studydesign 
number of patients 340 
Outcome HAMD reduction/response rate: 
Placebo: -9.20/-31,9 % 
LI 160: -8,68/-23,9 % 
Sertraline: -10.53/-24,8 % 
 
Conclusion: No efficacy of LI 160 and of sertraline in treatment 
of moderately severe major depression. Possible reason: low 
assay sensitivity. 
Comment No efficacy despite of increase of dosage during study 
 
Study Montgomery et al 2000 
Indication mild to moderate depression (DSM-IV) 
Duration of use 12 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre n=18 
Studydesign 
number of patients 248 
Outcome Conclusion: 
There is no statistically significant difference between placebo 
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and LI 160. (HAMD-score after 6 weeks). Negative Outcome 
 
Study Vorbach et al 1997 
Indication severe mild to moderate major depression according to ICD-10 F 
33.2, recurrent, without psychotic symptoms 
Duration of use 6 weeks 
Daily dosage 1800 mg 
Single dosage 600 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled  
reference-
controlled 
150 mg/d imipramine 
multicentre n=20 
Studydesign 
number of patients 209 
Outcome HAMD (17 items) reduction: 
LI 160:from 25.3±4.7 to 14.4±6.1 
Imipramine: from 26.1±4.8 to 13.4±5.9 
 
Conclusion: 
Efficacy not statistically equivalent, equivalence only in 
subgroups with more than 33% and 50% reduction of the HAMD 
total score. Superiority for LI 160 in adverse events.  
 
Study Wheatley 1997 
Indication mild to moderate major depression (HAMD-17 score: 17-24; 
according to DSM-IV) 
Duration of use 6 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
75 mg/d amitriptyline 
multicentre n=19 
Studydesign 
number of patients 165 
Outcome HAMD reduction: 
LI 160: from 20 to 10 
Amitriptyline: from 21 to 6 
 
Conculusion: 
No statistically significant difference between LI 160 and 
amitriptyline; Hypericum is better tolerated. 
 
Study Harrer et al 1994 
Indication moderately severe depressive episodes, according to ICD-10, F 
32.1 (HAMD 17-items >- 16) 
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Duration of use 4 weeks  
Daily dosage 900 mg/d  
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-controlled Maprotiline (3 x 25 mg) 
multicentre n=6 
Studydesign 
number of patients 102 
Outcome HAMD reduction: 
LI 160: 20.5 -> 12.2, no statistically significant difference 
compared to maprotiline. 
Maprotiline: 21.5 -> 10.5 
Responder rate: 61% in hypericum, 67% in maprotiline 
 
Onset of effects up to the second week of treatment. After 2 weeks 
of treatment more pronounced effect with maprotiline, after 4 
weeks both groups similar. 
 
Study Shelton et al 2001 
Indication major depression (HAMD: ≥ 20 for more than 2 years, according 
to DSM-IV: major depression disorder, single episode or recurrent, 
without psychotic features) 
Duration of use 8 weeks 
Daily dosage 900 mg/d for 4 weeks, in case of not adequate response increase to 
1200 mg/d  
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre n=11 
Studydesign 
number of patients 200 
Outcome Response rate in the ITT-analysis: 
LI 160: 26,5 % (for statistical significance 36,1 % is needed) 
Placebo: 18,6 % 
In Hypericum group a significant greater proportion of remissions. 
 
Conclusion: LI160 is not effective in treatment of major 
depression; good compliance: only adverse effect: headache. 
Comment High number of patients with chronic depression. Sponsoring by 
Pfilzer 
 
Study Hänsgen et al 1996 
Indication mild to moderate major depression, according to DSM-III-R 
(HAMD >- 16) 
Duration of use 4 weeks (+2 weeks) 
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Daily dosage 900 mg/d  
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-controlled no 
multicentre n=17 
Studydesign 
number of patients 102 
Outcome HAMD reduction: 
LI 160: 21.0 -> 8.9, statistically significant compared to placebo. 
Placebo: 20.4 -> 14.4 
Responder rate: 70% in hypericum, 24% in placebo 
Further 2 weeks of verum-treatment in both groups: similar 
improvement in the former placebo-group like in the first 2 weeks 
of treatment in the verum group. 
 
 
Study Hänsgen et al 1994 
Indication mild to moderate major depression, according to DSM-III-R 
(HAMD >- 16) 
Duration of use 4 weeks (+2 weeks) 
Daily dosage 900 mg/d  
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-controlled no 
multicentre n=11 
Studydesign 
number of patients 67 
Outcome HAMD reduction: 
LI 160: 21.8 -> 9.2, statistically significant compared to placebo. 
Placebo: 20.4 -> 14.7 
Responder rate: 81% in hypericum, 26% in placebo 
Further 2 weeks of verum-treatment in both groups: similar 
improvement in the former placebo-group like in the first 2 weeks 
of treatment in the verum group. 
 
 
Study Sommer et al 1994 
Indication Depressive symptoms according ICD-09 300.4 (neurotic 
depression) and 309.0 (brief depressive reaction). 
Duration of use 4 weeks  
Daily dosage 900 mg/d  
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
Studydesign 
placebo-controlled yes 
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reference-controlled no 
multicentre n=3 
number of patients 105 
Outcome Only graphical presentation of data; improvement under hypericum 
after 4 weeks significant at a 1% level compared to placebo. 
Responder rate: 67% in hypericum, 28% in placebo 
 
 
Metanalaysis of clinical studies with LI 160 (Linde 2007) 
 
 
 
Conclusion:  
Reference controlled studies: all studies included patients with major depression; similar or 
insignificant less efficacy compared to standard antidepressants; in some studies no difference 
between hypericum, reference medication and placebo. Only one study (Vorbach et al 1997) 
was designed for proof of equivalence.  
Placebo controlled studies: tendency that in older studies (published before 2000) better 
outcome for hypericum; modern studies also with negative outcome. 
Studies including patients with more severe depressive episodes (daily dosage up to 1800 mg 
extract) do not show sufficient efficacy. 
 
 
Extract WS 5570:  
 
Extract WS 5570 
Extraction solvent 80 % 
methanol 
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DER 4-7:1 
Hypericin 0,12-0,28 % 
Hyperforin 3-6 % 
 
The extraction solvent and the declared amount of Hypericine of this extract are identical with 
that of LI 160.  
 
Study Anghelescu et al 2006 
Indication moderate to severe depression according to DSM-IV criteria: 
296.22, 296.23, 296.32 and 296.33 (HAMD 17-item: ≥ 22) 
Duration of use 6 weeks of acute treatment 
Daily dosage 900 mg or 1800 mg; dose increase in week 2 in patients with 
HAMD improvement <20% 
Single dosage 300 mg or 600 mg 
Relapse Patients with a HAM-D total score decrease of >=50% during the 
6 weeks of acute treatment were asked to continue the treatment 
for another 16 weeks (n=133) 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
20/40 mg/d paroxetine; dose increase in 
week 2 in patients with HAMD 
improvement <20% 
multicentre n=21 
Studydesign 
number of patients 133 
Outcome HAMD reduction: 
WS 5570: .from 25.3+/-2.5 to 4.3+/-6.2 
Paroxetine: from 25.3+/-2.6 to 5.2+/-5.5 
 
During maintenance treatment alone 61.6% of the hypericum 
group and 54.6% of the paroxetine group showed additional 
reduction of HAMD score. Remission occurred 81.6% in the 
hypericum group and 71.4% in the paroxetine group. 3 Patients 
under Hypericum and 2 patients under paroxetine showed an 
increase in HAMD score of >5 during continuation treatment  
 
Conclusion: WS 5580 an paroxetine are similarly effective in 
preventing relapse in a continuation treatment after recovery from 
an episode of modeate to severe depresssion 
 
Study Szegedi et al 2005 
Indication moderate to severe major depression (HAMD 17-item: ≥ 22; 
DSM-IV: 296.22, 296.23, 296.32, 296.33) 
Duration of use 6 weeks 
Daily dosage 900 mg-1800 mg; dose increase in week 2 in patients with 
HAMD improvement <20% 
Single dosage 300 mg-600 mg 
Relapse Responders (decrease in total HAMD score ≥ 50%) were invited 
to participate in a four month double blind maintenance phase 
Studydesign randomized yes 
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double blind yes 
placebo-controlled no 
reference-
controlled 
20 mg-40 mg/d paroxetine; dose increase 
in week 2 in patients with HAMD 
improvement <20% 
multicentre n=21 
number of patients 251 
Outcome HAMD recuction/ % responder: 
WS 5570: -14.4 / 71% 
Paroxetine: -11.4 / 60% 
 
Conclusion: WS 5570 is as effective as paroxetin in the treatment 
of moderate to severe major depression 
Comment The results of the maintenance phase will be published 
eslewhere. 
 
Study Lecrubier et al 2002 
Indication mild to moderate major depression (single or recurrent episode, 
DSM-IV code: 296.21, 296.22, 296.32, HAMD 17-item: 18-25) 
Duration of use 6 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre n=26 
Studydesign 
number of patients 375 
Outcome HAMD reduction/Responders 
WS 5570: -9,9/52,7 % 
Placebo: -8,1/42,3 % (The difference is significant) 
 
Conculusion: WS 5570 is safe and more effective than placebo in 
the treatment of mild to moderate major depression 
 
 
Study Kasper et al 2006 
Indication mild or moderate major depressive episode (single or recurrent 
episode, DSM-IV criteria: 296.21, 296.31, 296.21, 296.22, 
296.31, 296.32; HAMD 17-item: ≥ 18, “depressive mood” ≥ 2) 
Duration of use 6 weeks 
Daily dosage 600-1200 mg 
Single dosage 600 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
Studydesign 
reference-
controlled 
no 
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multicentre n=16 
number of patients 332 
Outcome More patients in the WS 5570 1200 mg group met the criterion of 
remission (HAMD: ≤ 7 at treatment end) 
 
HAMD reduction: 
WS 5570 600 mg: -11.6 ± 6,4 
WS 5570 1200 mg: -10.8 ± 7,3 
Placebo: -6.0 ± 8,1 
 
Conclusion: WS 5570 is safe and more effective than placebo in 
treatment of mild to moderate depression. 
 
Study Kasper et al 2008 
Indication recurrent episode of moderate major depression; HAMD 17-item: 
≥ 20, ≥ 3 previous episodes in 5 years (ICD-10 F33.0. F33.1, 
DSM-IV 296.3) 
Duration of use 6 weeks single blind acute treatment, then 26 weeks double blind 
continuation treatment, then 52 weeks double blind maintenance 
treatment 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse + 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre yes 
Studydesign 
number of patients 426 
Outcome Relapse rates: Hypericum 18.1%; placebo 25.7% 
Average time to relapse: Hypericum 177 days; placebo 163 days 
 
Conclusion: WS 5570 showed a beneficial effect in preventing 
relapse after recovery from acute depression. Tolerability in 
continuation and long-term maintenance treatment was on the 
placebo level.. 
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Conclusion: All studies are well designed. All studies report superiority compared to placebo 
or non-inferiority compared to standard medication. 
 
Comparison with LI 160: 
In contrast to the recent studies published for LI 160 all modern studies for WS 5570 
demonstrated a positive outcome for hypericum. Since the extracts LI 160 and WS 5570 are 
very similar in their key parameters, it seems to be justified to combine the results. It can be 
concluded that the efficacy of this type of extract in the treatment of mild to moderate severe 
depression is well documented. 
 
 
Extract Ze 117: 
 
Extract Ze 117 
Extraction solvent There are differing 
informations on the 
extraction solvent: 50 % 
ethanol or ethanol 49% 
m/m : 2-propanol (97.3 : 
2.7) 
DER 4-7:1 
Hypericin 0,2 %  
Hyperforin nearly free of hyperforin 
 
Information on the refinement of the extract in order to reduce the content of hyperforin are 
not available. 
 
Study Schrader 2000 (=Friede et al 2001?) 
Indication mild to moderate depression (ICD-10; F 32-0 and F 32-1, HAMD 
scale (21-item) 16-24) 
Duration of use 6 weeks 
Daily dosage 500 mg 
Single dosage 250 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
20 mg fluoxetine 
Studydesign 
multicentre n=7 
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number of patients 240 
Outcome HAMD reduction: 
Ze 117: from 19.65 to 11.54/-7,25 
Fluoxetine: from 19.50 to 12.20/-8,11 
 
Conclusion: 
Hypericum and fluoxetine are equipotent. Ze 117 safety was 
superior to fluoxetine. 
Comment Contact of patients with investigators only at the beginning of the 
study and after 6 weeks in order to minimize the placebo effect. 
Nearly identical data in the publication compared to Friede et al 
2001. However, no coincidence of the authors and the sponsor. 
 
Study Friede et al 2001 (=Schrader 2000?) 
Indication mild to moderate depressive episodes (ICD-10: F 32.0, F 32.1; 
HAMD range: 16-24) 
Duration of use 6 weeks 
Daily dosage 500 mg 
Single dosage 250 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
20 mg fluoxetine 
multicentre n=7 
Studydesign 
number of patients 240 
Outcome HAMD reduction/responder rate: 
Ze 117: from 19.7 to 11.5/60 % 
Fluoxetine: from 19.5 to 12.2/40 % 
 
Conclusion: 
Ze 117 is equipotent to fluoxetine in the treatment of mild to 
moderate depression 
Comment There was a marked decrease of depressive agitation (pre-post 
comparison: 46%) and anxiety symptoms (44%) during the 
therapy with St. John's wort. Depressive obstruction (44%) and 
sleep disorders (43%) were reduced during the treatment. 
Nearly identical data in the publication compared to Schrader et 
al 2000. However, no coincidence of the authors and the sponsor. 
 
Study Woelk 2000 
Indication mild to moderate depression (ICD-10 codes F32.0, F33.0, F32.1, 
F 33.1; HAMD score (17-item) > 17) 
Duration of use 6 weeks 
Daily dosage 500 mg 
Single dosage 250 mg 
Relapse - 
randomized yes Studydesign 
double blind yes 
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placebo-controlled no 
reference-
controlled 
150 mg/d imipramine 
multicentre n=40 
number of patients 324 
Outcome HAMD reduction: 
Ze 117: from 22.4 to 12.0 
Imipramine: from 22.1 to 12,75 
 
Conclusion: Ze 117 and imipramine are therapeutically 
equivalent in the treatment of mild to moderate depression. In the 
treatment of depression with anxiety hypericum has more benefit. 
There are fewer adverse events in the Ze 117 group. 
Comment The dosage of imipramine is relatively high, which could be the 
reason the high number of drop outs in the reference group. 
 
Study Schrader et al 1998 
Indication mild to moderate depression (ICD-10; F 32-0 and F 32-1) 
Duration of use 6 weeks 
Daily dosage 500 mg (corresponding to 1 mg hypericin daily) 
Single dosage 250 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre n=16 
Studydesign 
number of patients 162 
Outcome HAMD (21-item) reduction / % responder: 
Ze 117: from 20,13 to 10,53 / 56% 
Placebo: from 18,76 to 17,89 / 15% 
 
Conclusion: ZE 117 is significantly superior compared to placebo 
and safe in treatment of mild to moderate depression 
Comment Contact of patients with investigators only at the beginning of the 
study and after 6 weeks in order to minimize the placebo effect. 
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Conclusion: The superiorioty of the extract ZE 117 against placebo and the non-inferiority 
against imipramin and fluoxetin could be demonstrated. Compared with the results obtained 
with the extracts LI 160 and WS 5570 it can be concluded that the content of hyperforin in the 
extract is not correlated with clinical efficacy. The extract is according to the manufacturer at 
least since 1996 in Germany on the market. Therefore the minimum of 10 years of medicinal 
use is fulfilled. 
 
 
Liquid extract  
 
Extract Hyperforat drops 
Extraction solvent 50 % ethanol 
DER 0.5:1 
Hypericin 2 mg / ml 
Hyperforin not specified 
 
Study Hoffmann et al 1979 
Indication mild to severe forms of depression 
Duration of use 6 weeks 
Daily dosage 90 drops (= 3.6 ml = 7.2 mg hypericin) 
Single dosage 30 drops 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
- 
multicentre - 
Studydesign 
number of patients 60 
Outcome Not standardised symptom score with 47 items; improvement 
under hypericum after 6 weeks of 61.4%, in placebo group of 
16.8%. 
Responder: 
Hypericum: 80% 
Placebo: 33% 
Comment Lack of statistical evaluation; inadequate study design 
 
 
 
Conclusion: An old study (inadequate study design) shows superiority against placebo. No 
data are available on comparison to synthetic antidepressants. 
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Extract STW 3 
 
Extract STW 3 
Extraction solvent 50 % ethanol 
DER 5-8:1 
Hypericin mean 0.21% 
Hyperforin mean 3,3% 
Flavonoids mean 7.11% 
 
 
Study Gastpar et al 2005 
Indication moderate depressive disorder (according to ICD-10 criteria: 
F32.1 or F33.1; HAMD 17-items: 20-24) 
Duration of use 12 weeks 
Daily dosage 612 mg 
Single dosage 612 mg 
Relapse after 12 weeks additional treatment for 12 weeks of n=161 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
50 mg sertraline 
multicentre n=18 
Studydesign 
number of patients 241 
Outcome HAMD reduction: (week 12/week 24) 
STW 3: from 22.0 to 8.3/5.7 
Sertraline: from 22.1 to 8.1/7.1 
 
Conclusion: STW 3 is therapeutically equivalent to sertraline in 
moderate depression and it is well tolerated. 
Comment Single daily dose 
 
 
 
Conclusion: an adequate study demonstrates non-inferiority compared to sertraline (50 mg). 
 
 
Esbericum capsules:  
Daily dosage: 213-252 mg extract;  
 
Extract Esbericum 
Extraction solvent 60 % ethanol 
DER 2-5,5:1 
Hypericin 0.1% 
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Hyperforin not specified 
Flavonoids not specified 
 
Study Bergmann et al 1993 
Indication mild to moderate depression (ICD-10 F32.0, F32.1, F33.0, F33.1) 
Duration of use 6 weeks 
Daily dosage 213-252 mg extract (Corresponding to 0.75 mg hypericin) 
Single dosage  
Relapse - 
randomized yes 
placebo-controlled yes 
reference-
controlled 
30 mg amitriptylin/day 
multicentre n=1 
Studydesign 
number of patients 80 
Outcome HAMD reduction / % responder: 
Esbericum: from 15.82 to 6.43 / 84.2% 
Amitriptylin: from 15.26 to 6.65 / 73.7% 
 
From the fact that the low dosage of amitriptylin was effective it 
can be assumed that only patients with mild depression were 
included. 
Comment Low dosage of amitriptylin; study design insufficient 
 
 
 
Conclusion: The results do not allow the conclusion, that this type of extract in the chosen 
posology is suitable for the treatment of mild or moderate depression. 
 
 
Extract STEI 300:  
 
Extract STEI 300 
Extraction solvent 60 % ethanol 
DER 5-7:1 
Hypericin 0.2-0.3% 
Hyperforin 2-3% 
Flavonoids not specified 
 
Study Philipp et al 1999 
Indication moderate depression according to ICD-10 (codes F32. 1 and 
F33.1) (HAMA score > 18) 
Duration of use 8 weeks 
Daily dosage 1050 mg 
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Single dosage 350 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
100 mg/d imipramine (titrated within 4 
days from 50 mg) 
multicentre n=18 
Studydesign 
number of patients 263 
Outcome HAMD reduction / % responder: 
STEI 300: 22.7-> 7.3 / 76% 
Placebo: 22.7-> 10.6 / 63% 
Imipramine: 22.2-> 8.0 / 66.7% 
 
Conclusion: STEI 300 is as effective as imipramine and more 
effective than placebo in the treatment of moderate depression 
and it is safe. 
Comment Study of high methodological quality 
 
 
 
Conclusion: superiority against placebo and non-inferiority against imipramine (100 mg) 
could be demonstrated. 
 
 
Extract LoHyp-57:  
 
Extract LoHyp-57 
Extraction solvent 60 % ethanol 
DER 5-7:1 
Hypericin 0.2-0.3% 
Hyperforin 2-3% 
Flavonoids not specified 
 
Extract identical to STEI 300, but different dosage form and posology. 
 
Study Harrer et al 1999 
Indication mild to moderate major depression according to ICD 10 (F32.0, 
F32.1) 
Duration of use 6 weeks 
Daily dosage 800 mg 
Single dosage 400 mg 
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Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
20 mg fluoxetine (= 22.4 mg fluoxetine 
HCl) 
multicentre n=17 
Studydesign 
number of patients 149 
Outcome HAMD (17-items) reduction: 
LoHyp 57: from 16.60 to 7.91 (mild: from 14.21 to 6.21; 
moderate: from 18.73 to 9.43) 
Fluoxetine: from 17.18 to 8.11 (mild: from 15.21 to 7.46; 
moderate: from 19.10 to 8.75) 
 
Responder rate: 
LoHyp 57: 71.4% (mild subgroup: 81.8%; moderate subgroup: 
62.2%) 
Fluoxetine: 72.2% (mild subgroup: 76.9%; moderate subgroup: 
67.5%) 
 
Conclusion: LoHyp 57 is equivalent to fluoxetine in treatment of 
mild to moderate major depression particularly in elderly 
patients. 
Comment No confidence intervals shown in the publication, therefore the 
non-inferiority is formally not demonstrated; patients 60-80 years 
 
 
 
Conclusion: 800 mg of LoHyp-57 is equivalent to 20 mg fluoxetine in the treatment of mild to 
moderate major depression. 
 
 
Extract STW3-VI:  
 
Extract STW3-VI 
Extraction 
solvent 
80 % ethanol 
DER 3-6:1 
Hypericin mean 0.26% 
Hyperforin mean 3.0% 
Flavonoids mean 7.17% 
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Study Gastpar et al 2006 
Indication moderate depression (HAMD 17-items score: 20-24, ICD-10. 
F32.1, F33.1, according to DSM-IV major depressive episode 
and recurrent major depression) 
Duration of use 6 weeks 
Daily dosage 900 mg 
Single dosage 900 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
20 mg citalopram 
multicentre n=21 
Studydesign 
number of patients 388 
Outcome HAMD reduction / % responder: 
Hypericum: 21.9 -> 10.3 / 54.2% 
Citalopram: 21.8-> 10.3 / 55.9% 
Placebo: 22.0 -> 13.0 / 39.2% 
 
Conclusion: 
The hypericum group was statistically non-inferior to citalopram 
and significantly superior to the placebo. 
Comment Study of high methodological quality 
 
Study Uebelhack et al 2004 
Indication moderate depressive disorders (ICD-10 F32.1, F33.1) and 
HAMD (17-items) score : 20-24 
Duration of use 6 weeks 
Daily dosage 900 mg 
Single dosage 900 mg 
Relapse  
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre n=1 
Studydesign 
number of patients 140 
Outcome HAMD reduction / % responder: 
STW3-VI: 22.8 -> 11.8 / 58.6% 
Placebo:  22.6 -> 19.2 / 5.7% 
 
Conclusion: STW3-VI in a single daily dose is superior to 
placebo. 
 
Comment Conspicuously low responder rate under placebo. This is 
explained by the authors that primarily patients with moderate 
depression were included, while other studies included also a 
higher number of patients with mild depression. 
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Conclusions: superiority against placebo and non-inferiority against citalopram (20 mg) could 
be demonstrated. 
 
 
Extract WS 5572:  
 
Extract WS 5572 
Extraction 
solvent 
60 % ethanol 
DER 2,5-5:1 
Hypericin not specified 
Hyperforin 4-5 % (Rychlik et al 2001, Lackmann et al 
1998) 
1,5 % (Kalb et al 2001) 
 
Study Rychlik et al 2001 
Indication mild to moderate depression (based on CGI) 
Duration of use 7 weeks 
Daily dosage 600 mg/1200 mg 
Single dosage 600 mg 
Relapse - 
randomized no 
double blind no 
placebo-controlled no 
reference-
controlled 
comparison of 600 mg and 1200 mg daily 
multicentre n=446 
Studydesign 
number of patients 2166 
Outcome Responder: 
600 mg: 83,7 % 
1200 mg: 86,9 % 
 
Conclusion: Good effectiveness and tolerability of WS 5572 
Comment Observational study 
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Study Kalb et al 2001 
Indication mild to moderate major depressive disorder (according to DSM-
IV criteria) (DSM-IV code: 296.21, 296.31, 296.22, 296.32, 
HAMD (17-items): ≥ 16) 
Duration of use 6 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
no 
multicentre n=11 
Studydesign 
number of patients 72 
Outcome HAMD reduction / % responder: 
WS 5572: 19.7 -> 8.9 / 62.2% 
Placebo: 20.1 -> 14.4 / 42.9% 
 
Conclusion: superior compared to placebo  
Comment Efficacy was already statistically significant at day 28 
Adaptive 2-stage design 
 
Study Laakmann et al 1998 
Indication mild or moderate depression according to DSM-IV criteria, 
HAMD ≥ 17 
Duration of use 6 weeks 
Daily dosage 900 mg 
Single dosage 300 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled yes 
reference-
controlled 
900 mg WS 5573 
multicentre n=11 
Studydesign 
number of patients 147 
Outcome HAMD reduction / % responder: 
WS 5572: 20.9 -> 10.7 / 49.0% 
WS 5573: 20.3 -> 11.8 / 38.8% 
Placebo: 21.2 -> 13.3 / 32.7% 
 
Conclusion: 
WS 5572 (5% hyperforin) was superior to placebo  
WS 5573 (0.5% hyperforin) and placebo were descriptively 
comparable 
The therapeutic effect depends on the content of hyperforin. 
Comment WS 5572 and WS 5573 are produced with the identical 
manufacturing process (identical DER, extraction solvent), the 
only difference between the extracts relates to the content of 
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hyperforin. The fingerprint chromatograms of the two extracts 
are except for hyperforin identical. It is not mentioned how the 
differences in the conbtent of hyperforin are achieved. 
The negative outcome for the extract with low content of 
hyperforin is in contrast to the positive findings with the extract 
ZE 117, which is said to be nearly free of hyperforin. 
 
 
 
Conclusion: WS 5572 is superior to placebo in the treatment of mild to moderate major 
depression. 
 
 
Extract Calmigen:  
 
Extract Calmigen 
Extraction 
solvent 
not specified 
DER not specified 
Hypericin 0.3% 
Hyperforin not specified  
 
Study Behnke et al 2002 
Indication mild to moderate depression (ICD-10 F32), HAMD (17-items) 
score 16-24 
Duration of use 6 weeks 
Daily dosage 300 mg 
Single dosage 150 mg 
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
40 mg fluoxetin 
multicentre n=446 
Studydesign 
number of patients 70 
Outcome HAMD reduction / % responder; 
Calmigen: 20.0 -> 10.0 / 55% 
Fluoxetin: 20.7 -> 8.7 / 66% 
Comment Number of patients too small for comparison of efficacy. 
Not to be confused with Calmigen capsules (300 mg Hypericum 
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extract, extraction solvent methanol 80%, 0.3% hypericin, 
authorized in DK) 
 
 
Extract Hyperiforce:  
 
Extract Hyperiforce 
Extraction 
solvent 
not specified 
DER 4-5:1 (shoot tips) 
Hypericin 0.5% 
Hyperforin not specified  
 
Study Lenoir et al 1999 
Indication mild to moderate depression (ICD-10) 
Duration of use 6 weeks 
Daily dosage corresponding 0.17 mg, 0.33 mg or 1 mg hypericin 
Single dosage  
Relapse - 
randomized yes 
double blind yes 
placebo-controlled no 
reference-
controlled 
comparison of different dosaged 
multicentre n=38 
Studydesign 
number of patients 348 
Outcome Reduction in HAMD score from initially 16-17 to 8-9 in all 
groups. Resonder rate 62%-68%. The extract was effective on all 
three dosages. 
Comment No placebo group 
 
 
Psychotonin (Liquid extract, DER 1: 5-7, extraction solvent ethanol 50%) 
All studies performed with this type of extract ( Harrer et al 1991, Osterheider et al 1992, 
Quandt et al 1993, Schlich et al 1987, Schmidt et al 1989) are not convincing from the current 
point of view. The methodology is inadequate, the number of included patients is small, the 
drop-out-rate is considerably high. The studies do not fulfil the criteria for well-established 
use. 
 
 
Overall metanalysis 
Roder et al (2004) published a meta-analysis of effectiveness and tolerability of treatment of 
mild to moderate depression with hypericum extracts. 
The results demonstrate a significant superiority of hypericum extracts over placebo (mean 
response: Hypericum: 53.3 % and placebo: 32.7 %). Compared to standard antidepressive 
hypericum is similar effective for the treatment of depression (mean response: Hypericum: 
53.2 %, synthetic antidepressive: 51.3 %). In the sub group of mild to modeate depression 
hypericum showed better results against the standard antidepressive groupe (mean response: 
59.5 %/52.9 %) and a better side-effect profile. The fail-safe-N-test indicates that 423 studies 
with no effect would be needed to negate the presented result for placebo studies. 
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Werneke et al (2004) came to similar results. They found that the effect sizes in recent studies 
were smaller than those resulted form earlier studies. 
 
Linde et al (2005) concluded that the available data for major depression is confusing. While 
hypericum has minimal benefical effects over placebo, other trials suggest that hypericum and 
standard antidepressives are equal. 
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Assessor’s conclusion: 
 
Overview of extracts with predominately positive study outcome (Superiority against placebo, 
equivalence to reference medication): 
 
ICD-10 F32.0: mild depressive episode 
ICD-10 F32.1: moderate depressive episode 
ICD-10 F33.0: recurrent depressive disorder, current episode mild 
ICD-10 F33.1: recurrent depressive disorder, current episode moderate 
DSM-IV 296.21: major depressive disorder, single episode, mild 
DSM-IV 296.22: major depressive disorder, single episode, moderate 
DSM-IV 296.23: major depressive disorder, single episode, severe without psychotic features 
DSM-IV 296.31: major depressive disorder, recurrent, mild 
DSM-IV 296.32: major depressive disorder, recurrent, moderate 
DSM-IV 296.33: major depressive disorder, recurrent, severe without psychotic features 
 
 single episode recurrent single recurrent 
 mild moderate mild moderate severe severe 
 ICD-10 
F32.0 
DSM-
IV 
296.21 
ICD-10 
F32.1 
DSM-
IV 
296.22 
ICD-10 
F33.0 
DSM-
IV 
296.31 
ICD-10 
F33.1 
DSM-IV 
296.32 
DSM-IV 
296.23 
DSM-IV 
296.33 
A: LI 160   x   x  x   
B: WS 5570    x    x x x 
C: STW3-VI   x    x    
D: STEI 300   x    x    
E: LoHyp-57 x  x        
F: WS 5572  x  x  x  x   
G: STW3   x    x    
H: ZE 117 x  x  x  x    
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 DER extraction solvent % hypericin % hyperforin % flavonoids daily dosage duration 
A: LI 160 3-6:1 methanol 80% 0.12-0.28 app. 4.5% app. 8.3% 900 mg 4-12 weeks 
B: WS 5570 4-7:1 methanol 80% 0.12-0.28 3-6% not specified 600-1800 mg 6/26 weeks 
relapse + 
C: STW3-VI 3-6:1 ethanol 80% 0.26% (mean) 3.0% (mean) 7.17% (mean) 900 mg 6 weeks 
D: STEI 300 5-7:1 ethanol 60% 0.2-0.3% 2-3% not specified 1050 mg 8 weeks 
E: LoHyp-57 5-7:1 ethanol 60% 0.2-0.3% 2-3% not specified 800 mg 6 weeks 
F: WS 5572 2.5-5:1 ethanol 60% not specified 4-5% not specified 600-1200 mg 6-7 weeks 
G: STW3 5-8:1 ethanol 50% 0.21% (mean) 3.3% (mean) 7.11% (mean) 612 mg 12 weeks 
H: ZE 117 4-7:1 ethanol 50% 0.2% nearly free not specified 500 mg 6 weeks 
Pharm.Eur. not 
specified 
ethanol 50-80% 
methanol 50-80% 
0.10-0.30% < 6.0% > 6.0%   
 
It is proposed to include the extracts types A-G into the monograph under well-established 
use with the indication ‘mild to moderate depressive episodes’. Since the informations on the 
extraction solvent of the extract of type H are inconsistent, it could not be included in the 
monograph. 
 
I.3.2.2.2 Somatoform disorders 
Volz et al (2002) conducted a multicentre, randomised, placebo controlled, 6-week trial 
comparing the efficacy of LI 160 (600 mg/day) and placebo in 151 out-patients suffering from 
somatization disorder (ICD-10: F45.0), undifferentiated somatoform disorder (F45.1), or 
somatoform autonomic dysfunctions (F45.3). The primary outcome measure was the decrease 
of the Hamilton Anxiety Scale, subfactor somatic anxiety (HAMA-SOM), during the trial 
period. The hypericum extract was superior effective concerning the primary outcome 
criterion HAMA-SOM [decrease from 15.39 (SD 2.68) to 6.64 (4.32) in the Hypericum group 
and from 15.55 (2.94) to 11.97 (5.58) in the placebo group (statistically significant difference, 
P=0.001)]. This was corroborated by the result of a statistically significant superior efficacy in 
the outcome criteria additionally used such as Clinical Global Impression, HAMA-total score, 
HAMA, subscore psychic anxiety, Hamilton Depression Scale, Self-Report Symptom 
Inventory 90 items - revised (SCL-90-R), and SCL-90-R, subscore somatic anxiety. The 
efficacy of LI 160 was preserved after splitting the population in those with and those without 
mild depressive symptoms [corrected]. Tolerability of LI 160 was excellent. The efficacy is 
independent of an existing depressive mood.  
 
In a prospective, randomized, placebo-controlled, and double-blind parallel group study, 184 
outpatients with somatization disorder (ICD-10 F45.0), undifferentiated somatoform disorder 
(F45.1), and somatoform autonomic dysfunction (F45.3), but not major depression, received 
either 300 mg of Hypericum extract extract LI 160 twice daily or matching placebo for 6 
weeks (Muller et al 2004). Six outcome measures were evaluated as a combined measure by 
means of the Wei Lachin test: Somatoform Disorders Screening Instrument--7 days (SOMS-
7), somatic subscore of the HAMA, somatic subscore of the SCL-90-R, subscores 
"improvement" and "efficacy" of the CGI, and the global judgment of efficacy by the patient. 
In the intention to treat population (N=173), for each of the six primary efficacy measures as 
well as for the combined test, statistically significant medium to large-sized superiority of 
Hypericum extract treatment over placebo was demonstrated (p <.0001). Of the Hypericum 
extract patients, 45.4% were classified as responders compared with 20.9% with placebo (p 
=.0006). Tolerability of Hypericum extract treatment was equivalent to placebo.  
 
I.3.2.2.3 Schizophrenia 
Hypericum extract LI160 has demonstrated a ketamine-antagonising effect. Therefore Murck 
et al (2006) examined whether LI160 reverses changes of a low dose ketamine on auditory 
evoked potentials (AEP) in healthy subjects. The authors performed a double-blind 
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randomized treatment with either 2 x 750 mg LI 160 or placebo given one week, using a 
crossover design, in 16 healthy subjects. A test-battery including AEPs, the oculodynamic test 
(ODT) and a cognitive test were performed before and after an infusion with 4 mg of S-
ketamine over a period of 1 hour. S-ketamine led to a significant decrease in the N100-P200 
peak to peak (ptp) amplitude after the placebo treatment, whereas ptp was significantly 
increased by S-ketamine infusion in the LI160 treated subjects. The ODT and the cognitive 
testing revealed no significant effect of ketamine-infusion and therefore no interaction 
between treatment groups. Provided that ketamine mimics cognitive deficits in schizophrenia, 
LI160 might be effective to treat these symptoms.   
 
I.3.2.2.4 Nootropic effects 
A study from Elis et al (2001) aimed to examine whether acute administration of standardized 
hypericum extract could exert a nootropic effect in normal human subjects. The study 
employed a double-blind, crossover, repeated-measures design. Twelve healthy young 
subjects completed the Cognitive Drug Research (CDR) memory battery, following 
administration of placebo, 900 mg and 1800 mg hypericum (Blackmore's Hyperiforte). The 
findings suggested that hypericum does not have an acute nootropic effect in healthy humans 
at these doses. However, there was some evidence for an impairing effect on accuracy of 
numeric working memory and delayed picture recognition at the higher dose. This observed 
impairment could be due to a sensitivity of these specific tasks to modulation by 
neurotransmitters that have been noted to have memory-impairing effects (e.g. y-
aminobutyric acid (GABA), serotonin).   
 
In a randomized, double-blind, cross over study of 12 healthy male volunteers received 
capsules with 255-285 mg St John's wort extract (900 µg hypericin content), 25 mg 
amitriptyline and placebo three times daily for periods of 14 days each with at least 14 days 
between (Siepmann et al 2002). The doses of amitriptyline and St John's wort extract are 
comparable with respect to their antidepressant activity. Neither St John's wort extract nor 
amitriptyline had an influence on cognitive performance such as choice reaction, psychomotor 
coordination, short-term memory and responsiveness to distractive stimuli. Amitriptyline but 
not St John's wort extract decreased self rated activity (P < 0.05). Both drugs caused 
significant qEEG changes. St John's wort extract increased theta power density. Amitriptyline 
increased theta as well as fast alpha power density. 
 
I.3.2.2.5 Cutaneous treatment 
In a half-side comparison study Schempp et al (2003) assessed the efficacy of a cream 
containing Hypericum: extract standardised to 1.5% hyperforin (verum) in comparison to the 
corresponding vehicle (placebo) for the treatment of subacute Atopic Dermatitis. The study 
design was a prospective randomised placebo-controlled double-blind monocentric study. In 
twenty one patients suffering from mild to moderate Atopic Dermatitis (mean SCORAD 44.5) 
the treatment with verum or placebo was randomly allocated to the left or right site of the 
body, respectively. The patients were treated twice daily over a period of four weeks. 
Eighteen patients completed the study. The severity of the skin lesions on the left and right 
site was determined by means of a modified SCORAD-index (primary endpoint). The 
intensity of the eczematous lesions improved on both sites of treatment. However, the 
hypericum-cream was significantly superior to the vehicle at all clinical visits (days 7, 14, 28) 
(p < 0.05). Skin colonisation with Staphylococcus aureus was reduced by both verum and 
placebo, showing a trend to better antibacterial activity of the hypericum-cream (p = 0.064). 
Skin tolerance and cosmetic acceptability was good or excellent with both the hypericum-
cream and the vehicle (secondary endpoints).  
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I.3.2.2.6 Premenstrual syndrome 
19 women with premenstrual syndrome who were in otherwise good physical and mental 
health and not taking other treatments for premenstrual syndrome were investigated in a 
prospective, open, uncontrolled, observational pilot study (Stevinson et al 2000). The 
participants took hypericum tablets for two complete menstrual cycles (1 x 300 mg hypericum 
extract per day standardised to 900 µg hypericin). Symptoms were rated daily throughout the 
trial using a validated measure. The Hospital Anxiety and Depression scale and modified 
Social Adjustment Scale were administered at baseline and after one and two cycles of 
treatment. There were significant reductions in all outcome measures. The degree of 
improvement in overall premenstrual syndrome scores between baseline and the end of the 
trial was 51%, with over two-thirds of the sample demonstrating at least a 50% decrease in 
symptom severity. Tolerance and compliance with the treatment were encouraging.  
 
Hicks et al (2004) performed a randomized, double-blinded, placebo-controlled trial, with two 
parallel treatment groups. After a no-treatment baseline cycle, volunteers were randomized to 
either Hypericum extract or placebo for a further two menstrual cycles. 169 normally 
menstruating women who experienced recurrent premenstrual symptoms were recruited onto 
the study. 125 completed the protocol and were included in the analysis. Study medication: 
600 mg of Hypericum extract (standardized to contain 1800 µg of hypericin) or placebo 
(containing lactose and cellulose). A menstrual diary was used to assess changes in 
premenstrual symptoms. The anxiety-related subgroup of symptoms of this instrument was 
used as the primary outcome measure. After averaging the effects of treatment over both 
treatment cycles it was found that there was a trend for Hypericum extract to be superior to 
placebo. However, this finding was not statistically significant.  
 
I.3.2.2.7 Menopausal symptoms 
In a drug-monitoring study Grube et al (1999) investigated 12 weeks of treatment with St. 
John's Wort, one tablet three times daily (900 mg Hypericum, Kira), in 111 women from a 
general medical practice. The patients, who were between 43 and 65 years old, had 
climacteric symptoms characteristic of the pre- and postmenopausal state. Treatment outcome 
was evaluated by the Menopause Rating Scale, a self-designed questionnaire for assessing 
sexuality, and the Clinical Global Impression scale. The incidence and severity of typical 
psychological, psychosomatic, and vasomotor symptoms were recorded at baseline and after 
5, 8, and 12 weeks of treatment. Substantial improvement in psychological and 
psychosomatic symptoms was observed. Climacteric complaints diminished or disappeared 
completely in the majority of women (76.4% by patient evaluation and 79.2% by physician 
evaluation). Of note, sexual well-being also improved after treatment with St. John's Wort 
extract. 
 
In a double-blind randomized, placebo-controlled, multicenter study (Chung et al 2007), 89 
peri- or postmenopausal women experiencing climacteric symptoms were treated with St. 
John's wort and black cohosh extract (Gynoplus), Jin-Yang Pharm., Seoul, Korea) or a 
matched placebo for 12 weeks. Climacteric complaints were evaluated by the Kupperman 
Index (KI) initially and at 4 and 12 weeks following treatment. Vaginal maturation indices, 
serum estradiol, FSH, LH, total cholesterol, HDL- cholesterol, LDL-cholesterol, and 
triglyceride levels were measured before and after treatment. From the initial 89 participants, 
77 completed the trial (42 in the Gynoplus group, 35 in the placebo group). Results: Baseline 
characteristics were not significantly different between the two groups. Mean KI scores and 
hot flushes after 4 and 12 weeks were significantly lower in the Gynoplus group. Differences 
- 67 - 
in superficial cell proportion were not statistically significant. HDL levels decreased in the 
control group from 60.20 +/- 16.37 to 56.63 +/- 12.67, and increased in the Gynoplus group 
from 58.32 +/- 11.64 to 59.74 +/- 10.54; this was statistically significant (p=0.04). 
Conclusion: Black cohosh and St. John's wort combination was found to be effective in 
alleviating climacteric symptoms and might provide benefits to lipid metabolism. 
 
I.3.2.3 Clinical studies in special populations (e.g. elderly and children) 
Depression in children 
 
Hübner et al (2001) investigated a hypericum extract in children under 12 years with 
symptoms of depression and psychovegetative disturbances. 
Study design: multi-center, post-marketing surveillance study; n=101 children under 12 years, 
dosage: 300 to 1800 mg per day. 
Based on the data available for analysis, the number of physicians rating effectiveness as 
'good' or 'excellent' was 72% after 2 weeks, 97% after 4 weeks and 100% after 6 weeks. The 
ratings by parents were very similar. There was, however, an increasing amount of missing 
data at each assessment point with the final evaluation including only 76% of the initial 
sample. Tolerability was good and no adverse events were reported. The results of this study 
suggest that Hypericum is a potentially safe and effective treatment for children with 
symptoms of depression. 
 
Findling et al (2003) conducted an open-label prospective outpatient pilot study of St. John's 
wort in juvenile depression. 
Youths 6 to 16 years of age meeting DSM-IV criteria for major depressive disorder, 
prospective, open-label, outpatient study; dosage: 3 x 150-300 mg. The extract is not further 
specified. 
33 children with a mean age of 10.5 (2.9) years were enrolled. After 4 weeks of St. John's 
wort therapy, 22 youths had their dose increased to 900 mg/day. Twenty-five of the patients 
met response criteria after 8 weeks of treatment. Overall, St. John's wort was well tolerated. 
The authors conclude that hypericum may be an effective treatment for youths diagnosed with 
major depressive disorder.  
 
Attention deficit, hyperactivity disorder 
In a randomized, double-blind, placebo controlled study (Weber et al 2008) 54 children aged 
6 to 17 years received 300 mg Hypericum extract (containing 0.3% Hypericine) 3 times daily 
for 8 weeks. All participants met the diagnostic criteria for ADHD. Hypericum did not 
improve the symptoms. 
 
 
Assessor’s conclusion on the use in the paedriatic population: 
The only relevant study is that performed by Hübner et al (2001) with the extract LI 160. 
However, this study was performed as post-marketing surveillance study and not as 
prospective phase III clinical trial. The efficacy and safety of the medication were assessed 
using very coarse rating scales but not generally accepted scales like HAMD-score. The data 
support the safety of a potential use in children but not the efficacy which is necessary for 
well-established use. Therefore the use in children and adolescents is not recommended. 
 
I.3.2.4 Assessor’s overall conclusions on clinical efficacy 
Dry extracts prepared with ethanol (50-80%) or methanol (50%) demonstrated clinical 
efficacy in the treatment of depression. Since relapse studies have been performed with 
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extracts containing more than 2% hyperforin these extracts are suitable for the treatment of 
mild to moderate major depression. Extracts containing less hyperforin should be used for the 
treatment of mild depression only. 
There are several new therapeutical approaches (smoking cessation, treatment of alcolohism, 
menopausal symptoms …) published. However, the clinical evidence is at the moment 
insufficient to be considered in a community monograph. 
The clinical data of the hyperforin cream demonstrate a great potential. However, the herbal 
preparation is less than 10 years in medicinal use; therefore well-established use is impossible 
in the monograph for now. 
 
I.3.3 Clinical Safety/Pharmacovigilance 
I.3.3.1 Patient exposure 
I.3.3.2 Adverse events 
 
A randomized, double-blind, crossover study was performed in healthy male volunteers aged 
22 to 31 years (25 +/- 3 years; mean +/- SD) years by Siepmann et al (2004). Subjects orally 
received capsules with 255 to 285 mg St. John's wort extract (900 µg hypericin content), 25 
mg amitriptyline, and placebo 3 times daily for periods of 14 days each with at least 14 days 
between. Vasoconstrictory response of cutaneous blood flow (VR) and skin conductance 
response (SR) following a single deep inspiration were employed as parameters of autonomic 
function. St. John's wort extract had no effect on VR and SR. 
 
Stevinson et al (2004) reviewed systematically the clinical evidence associating Hypericum 
extract with psychotic events. Seventeen case reports associated the use of Hypericum extract 
with psychotic events. In 12 instances, the diagnosis was mania or hypomania. Causality is in 
most cases possible. In no case was a positive rechallenge reported. These case reports raise 
the possibility that Hypericum extract may trigger episodes of mania in vulnerable patients.  
 
Linde performed in his meta-analysis (Linde et al 2005) also an analysis of safety. There was 
a trend towards lower probability of dropping out because of adverse effects in the hypericum 
groups compared to standard therapy. 
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Adverse events reported from clinical trials: 
Study Extract Daily dose Adverse events  
Lecrubier et al 
(2002) 
 
WS 5570 3 x 300 mg n=21 of 186 
Nausea (4.8 %) 
Headache (1.6 %) 
Dizziness (2.2 %) 
Abdominal pain (1.1%) 
Insomnia (1.6%) 
Kalb et al (2001) 
 
WS 5572 3 x 300 mg Sinusitis 
Bronchitis 
Common cold 
Schrader et al (1998) Ze 117 2 x 250 mg n=6 of 81 (7.4 %) 
Abdominal pain (2) Moderate 
Diarrhoea (1) Moderate 
Melancholia (1) Moderate 
Acute deterioration (1) Moderate 
Dry mouth (1) Mild 
Schrader (2000) Ze 117 2 x 250 mg 8 %  
only GI disturbances (5%) with an incidence greater 
than 2% 
Randlov et al (2006) PM235, 
(Cederroth 
Internationa
l AB, 
Sweden) 
3 x 270 mg mild, mainly headache, gastrointestinal symptoms 
Anghelescu et al 
(2006) 
WS 5570 900 mg or 1800 mg 26.8 % of 71 
no “typical adverse events (except: 1 allergic 
reaction to sunlight → early study termination) 
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0.006 AE/d 
 
Woelk (2000) Ze 117 2 x 250 mg 62 of 157 (39 %) 
Dry mouth (13) 
Headache (3) 
Sweating (2) 
Asthnia (2) 
Nausea (1) 
Philipp et al (1999) STEI 300 3 x 350 mg 0.5 events per patient (22 %) 
most frequently reported adverse event: Nausea 
Gastpar et al (2005) STW3 612 mg  9.8 %  related to study medication 
 Diarrhea (1) 
Serious adverse events (3): shoulder blade after 
falling down the stairs, somatic disorder, cerebral 
hemorrhage) 
Bjerkenstedt et al 
(2005) 
LI 160 3x 300 mg Adverse events: 38 
Patients with adverse events: 35.1 % 
Adverse events possibly related to study medication: 
24 
 
Body as a wohole (13) 
Gastro-intestinal system disorders (6) 
Autonomic nervous system disorders (10) 
Central & peripheral nervous system disorers (10) 
Skin and appendages disorders (9) 
Psychiatric disorders (2) 
Others (5) 
 
Kasper et al (2006) WS 570 600 mg or 1200 mg 
(2 x 600 mg) 
All adverse events. 49 (39.8 %) 
Serious events 1 (tendon rupture attributable to 
accidental injury) 
 
Ear and labyrinth disorders 3 (2.4 %) 
Gastrointestinal disorders 24 (19.5 %) 
General disorders and administraion site conditions 2 
(1.6 %) 
Infection and infestatons 7 (5.7 %) 
Injury, poisoning and procedural complications 1 
(0.8 %) 
Investigations 1 (0.8 %) 
Metabolism and nutrition disorders 1 (0.8 %) 
Musculosceletal and connective tissue disorder 1 
(0.8 %) 
Nervous system disorder 6 (4.9 %) 
Psychiatric disorders 2 (1.6 %) 
Renal and unrinary disorders 1 (0.8 %) 
Reproductive system and breast disorders 1 (0.8 %) 
Respiratory, thoracic and mediastinal disorders 4 
(3.3 %) 
Skin and subcutaneous disorders4 (3.3 %) 
Vascular disorders 1 (0.8 %) 
Fava et al (2005) LI 160 3 x 300 mg n=90 
most common adverse events. 
Headache (42 %) 
Dry mouth (22 %) 
Nausea (20 %) 
Gastrointestinal upset (20 %) 
Sleepiness (18 %) 
Shelton et al (2001) LI 160 900 mg/d for 4 
weeks, after this 
period no adequat 
Headache (41%) 
Abdominal pain (≥ 10 %) 
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response, new dose 
1200 mg/d 
Hypericum 
Depression Trial 
Study Group (2002) 
LI 160 900 to 1500 mg 
(3-5 x 300 mg) 
Diarrhea (21 %) 
Nausea (19 %) 
Anorgasmia (25 %) 
Forgetfulness (25 %) 
Frequent urination (27 %) 
Sweating (18 %) 
Swelling (19 %) 
Szegedi et al (2005) WS 5570 900 mg (3 x 300 
mg) – 1800 mg (3 
x 600 mg) 
adverse events per day 
 WS 5570 900 mg (0,029) 
 WS 5570 1800 mg (0,039) 
 
Upper abdominal pain (9.6 %) 
Diarrhoea (9.6 %) 
Dry mouth (12.8 %) 
Nausea (7.2 %) 
Fatigue (11.2 %) 
Dizziness (7.2 %) 
Headache (10.4 %) 
Sleep disorder (4 %) 
Increased sweating (7.2 %) 
 
highest incidence: 
Gastrointestinal disorders (59 events in 42 patients) 
Nervous system disorders ( 35 events in 29 patients) 
 
2 serious adverse events (psychic decompensation 
attributable to social problems, hypertensive crisis), 
both not caused by hypericum 
van Gurp et al (2002) ? 900 to 1800 mg/d Sleep disturbance (54.8 %) 
Anxiety (42.9 %) 
Sexual problems (11.9 %) 
Headaches (42.9 %) 
Dizziness (11.9 %) 
Tremor (19.1 %) 
Sweating (16.7 %) 
Dry mouth (38.1 %) 
Muscle spasms (11.9 %) 
Muscle or joint stiffness (19.1 %) 
Urinary problems (16.7 %) 
Difficulty digesting (19.1 %) 
Nausea or vomiting (9.5 %) 
Diarrhea (23.8 %) 
Lack of appetite (23.8 %) 
Heart palpitations (9.5 %) 
Fatigue (45.2 %) 
Pain (11.9 %) 
Blurred vision (14.3 %) 
 
1 serious adverse reaction (acute manic reaction) 
Laakmann et al 1998 WS 5573 
WS 5572 
3 x 300 mg WS 5573 (28.6 % of 49 patients) 
WS 5572 (28.6 % of 49 patients) 
 
Bronchitis (3/1) 
Influenza-like symptoms (2/0) 
Cough (2/0) 
Infection (1/0) 
Schrader 2000 Ze 117 2 x 250 mg 8 % Hypericum 
 
GI disturbances (5 %) 
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Lenoir et al 1999 Hyperiforce 
(provided 
by Biofroce 
AG, 
Roggwil, 
Switzerland
) 
3 x 1 tablet  
(standardised to 
either 0.17 mg, 
0.33 mg, or 1 mg  
total hypericin per 
day) 
There is no difference in AE with possible or 
probable causality in the three treatment-groups. 
 
Probable/Possible realation to study medication: 
Skin (0/3) 
Nerves (2/5) 
Psyche (1/1) 
Gastrointestinal tract (4/0) 
Oranism as a whole (0/2) 
Harrer et al 1999 LoHyp 57 2 x 400 mg n=12 (For this reason withdrawn: 6) 
Volz et al 2000 D-0496 2 x 250 mg n=18 at 17 % patients 
 
Influenza-like symptoms (7) 
Gastrointestinal tract (2) 
Skin (3) 
Infection of the urinary tract (1) 
Others (5) 
Gastpar et al 2006 STW3-VI 900 mg 17.2 % 
Total AE´s. 58 
Related: 10 
Gastrointestinal disorders (6) 
Ear and labyrinth disorders (1) 
Skin and subcutaneous tissue disorders (1) 
Wheatley 1997 LI 160 3 x 300 mg 37 % of the patients 
Dry mouth (5 %) 
Drowsiness (1 %) 
Sleepiness (2 %) 
Dizziness (1 %) 
Lethargy (1%) 
Nausea/Vomiting (7 %) 
Headache (7 %) 
Constipation (5 %) 
Pruritus (2 %) 
Vorbach et al 1997 LI 160 3 x 600 mg 23 % of the patients 
n=37 
Dry mouth (3) 
Gastric symptoms (5) 
tiredness/sedation (5) 
Restlessness (6) 
Tremor (2) 
Dizziness (5) 
Allergic skin reaction (1) 
Rychlik et al 2001 WS 5572 600 mg/1200 mg 17 patients 
n=21 (13 with relation to Hypericum) 
AE´x frequency < 1 % 
Skin irritation, pruritus 
Allergic exanthema 
Nervousness, restlessness 
Gastrointestinal disorders (4) 
Diarrhoe 
Insomnia 
 
According to the review by Greeson et al (2001) the overall incidence of ADR is in the range 
of 2%. The most commonly reported side effects were gastrointestinal irritations (0.6%), 
allergic reactions (0.5%), fatigue (0.4%) and restlessness (0.3%). In comparison, the overall 
ADR incidence for SSRIs is between 20% and 50%, including more serious side effects. 
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Additional case reports:  
Acute neuropathy after taking 500 mg of Hypericum powder per day and exposure to 
sunlight (Bove 1998) 
 
I.3.3.3 Serious adverse events and deaths 
Several case reports document psychotic side effects like mania and psychosis (review in 
Hammerness et al 2003). The majority of the affected persons had histories of affected illness, 
in most cases Hypericum was combined with other psychopharmaceuticals. The symptoms 
remitted after discontinuation of the medication. As a precaution Hypericum extracts should 
not be taken by persons with a history of mania or psychosis. Seizures are reported after 
overdose only (Karalapillai & Bellomo 2007). 
I.3.3.4 Laboratory findings 
I.3.3.4.1 Phototoxicity 
Hypericin 
Schempp et al (1999) describe the HPLC detection of hypericin and semiquantitative 
detection of pseudohypericin in human serum and skin blister fluid after oral single-dose (1 x 
6 tablets) or steady-state (3 x 1 tablet/day, for 7 days) administration of the Hypericum extract 
LI 160 in healthy volunteers (n = 12). Serum levels of hypericin and pseudohypericin were 
always significantly higher than skin levels (p </= 0.01). After oral single-dose administration 
of Hypericum extract the mean serum level of total hypericin (hypericin + pseudohypericin) 
was 43 ng/ml and the mean skin blister fluid level was 5.3 ng/ml. After steady-state 
administration the mean serum level of total hypericin was 12.5 ng/ml and the mean skin 
blister fluid level was 2.8 ng/ml. These skin levels are far below hypericin skin levels that are 
estimated to be phototoxic (>100 ng/ml).   
 
Dry extracts 
In a prospective randomized study Schempp et al (2003) investigated the effect of the 
Hypericum extract LI 160 on skin sensitivity to ultraviolet B (UVB), ultraviolet A (UVA), 
visible light (VIS) and solar simulated radiation (SIM). Seventy two volunteers of skin types 
II and III were included and were divided into six groups, each consisting of 12 volunteers. In 
the single-dose study the volunteers (n = 48) received 6 or 12 coated tablets (5400 or 10 800 
microgram hypericin). In the steady-state study the volunteers (n = 24) received an initial 
dose of 6 tablets (5400 microgram hypericin), and subsequently 3 x 1 tablets (2700 
microgram hypericin) per day for 7 days. Phototesting was performed on the volar forearms 
prior to medication and 6 h after the last administration of Hypericum extract. The erythema-
index and melanin-index were evaluated photometrically using a mexameter. After both 
single-dose and steady-state administration, no significant influence on the erythema-index or 
melanin-index could be detected, with the exception of a marginal influence on UVB induced 
pigmentation (p = 0.0471) in the single-dose study. The results do not provide evidence for a 
phototoxic potential of the Hypericum extract LI 160 in humans when administered orally in 
typical clinical doses up to 1800 mg daily. This is in accordance with previous 
pharmacokinetic studies that found hypericin serum and skin levels after oral ingestion of 
Hypericum extract always to be lower than the assumed phototoxic hypericin threshold level 
of 1000 ng/mL. 
 
The objective of a study by Schulz et al (2006) was to investigate the effect of two different 
hypericum extracts (STW 3, STW 3-VI) on photosensitivity with respect to minimal erythema 
dose (MED) after 14 days treatment. Both open, multiple-dose, one-phase studies were 
conducted in 20 healthy men, receiving one tablet per day. MED values were determined 
prior to hypericum extract administration (baseline) and after 14 days treatment using an 
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erythem tester emitting a light very similar to sun light (main emission spectrum: 285-350 
nm). Skin reactions with respect to MED were evaluated 12 h, 24 h (primary endpoint), 48 h 
and 7 days after irradiation. All volunteers reached steady-state of hypericin/pseudohypericin 
plasma concentrations before study day 14, when the irradiation under treatment conditions 
took place. In all subjects MED was measurable under baseline and under hypericum 
treatment conditions. With respect to the primary endpoint, in both studies, mean MED (24 h) 
were not significantly different between baseline and after 14 days hypericum treatment. 
However, individually photosensitivity of the skin could increase under treatment conditions, 
just as well photosensitivity could decrease or remain unchanged. There were no clinically 
relevant changes in the laboratory parameters, the vital signs, physical findings and other 
observations related to safety during the examinations. In one study (STW 3), two adverse 
events were reported, both described as hypersensitivity to light in mild intensity. The two 
studies showed that treatment with the two hypericum extracts under steady state and under 
prescribed conditions were safe medications without significant increases of photosensitivity. 
 
Hypericum oil 
Schempp et al (2000) investigated the effects of Hypericum oil (hypericin 110 microg/mL) 
and Hypericum ointment (hypericin 30 microg/mL) on skin sensitivity to solar simulated 
radiation. Sixteen volunteers of the skin types II and III were tested on their volar forearms 
with solar simulated radiation for photosensitizing effects of Hypericum oil (n=8) and 
Hypericum ointment (n=8). The minimal erythema dose (MED) was determined by visual 
assessment, and skin erythema was evaluated photometrically. With the visual erythema 
score, no change of the MED could be detected after application of either Hypericum oil or 
Hypericum ointment (P>0.05). With the more sensitive photometric measurement, an increase 
of the erythema-index after treatment with the Hypericum oil could be detected (P< or =0.01). 
The results do not provide evidence for a severe phototoxic potential of Hypericum oil and 
Hypericum ointment, detectable by the clinically relevant visual erythema score. However, 
the trend towards increased photosensitivity detected with the more sensitive photometric 
measurement could become relevant in fair-skinned individuals, in diseased skin or after 
extended solar irradiation. 
 
Assessor’s comment: 
The mentioned content of hypericin is in contrast to investigations from Maisenbacher et al 
(1992), these authors found only artefacts of hypericin. 
From traditional use of hypericum oil it is known that the exposure to sunlight of treated parts 
of the skin would lead to skin irritations. In traditional medicine it is recommended to protect 
treated skin from sunlight. 
 
I.3.3.5 Safety in special populations and situations 
I.3.3.5.1 Intrinsic (including elderly and children) /extrinsic factors 
I.3.3.5.2 Drug interactions 
The extent of induction of CYP3A varies among St. John's wort products and depends on 
hyperforin dose (Mueller et al 2006, Gutmann et al 2006). Products that do not contain 
substantial amounts of hyperforin (<1%) have not been shown to produce clinically relevant 
enzyme induction (Madabushi et al 2006). Hypericin may be assumed to be the P-
glycoprotein inducing compound, although the available evidence is less convincing (Mannel 
2004). 
Several meta-analyses are published on the pharmacokinetic interactions of hypericum with 
the cytochrome-P450 enzyme complex and P-glycoprotein (Pal et al 2006, Madabushi et al 
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2006, Whitten et al 2006, Zhou et al 2004, Mills et al 2004, Izzo 2004, Henderson et al 2002): 
Results from clinical studies and case reports indicate that self-administered hypericum 
extract reduce steady state plasma concentrations of alprazolam, amitriptyline, cyclosporine, 
tacrolimus, digoxin, fexofenadine, amprenavir, indinavir, lopinavir, ritonavir, saquinavir, 
benzodiazepines, methadone, nevirapine, simvastatin, theophyline, irinotecan, midazolan, 
triptans and warfarin. Hypericum has been also reported to cause bleeding and unwanted 
pregnancies when concomitantly administered with oral contraceptives. When combined with 
serotonin reuptake inhibitor, antidepressants (e.g. sertaline, paroxetine, nefazodone) or 
buspirone, hypericum extracts can cause serotonergic syndrome. Whitten et al (2006) 
concluded that in three studies, where the daily exposure to hyperforin was less than 4 mg, no 
significant effect on CYP3A4 could be detected. Brattström (2005, unpublished data, cited in 
Whitten et al 2006) tested the extract ZE117 in 16 females in a dose of 500 mg daily for 14 
days. The women started 3 months prior to the study taking 20 µg ethinyl oestradiol and 150 
µg desogestrel daily. Pharmacokinetic testing on days 7 and 22 after the treatment with ZE 
117 revealed no significant differences in ethinyl estradiol or 3-ketodesgestrel (active 
metabolite). It is not known whether a longer treatment with ZE117 would induce CYP3A4. 
Arold et al (2005) report from a pharmacokinetic interaction study with 240 mg Hypericum 
extract daily containing 3.5 mg Hyperforin. After treatment for 11 days no siginifcant changes 
in the primary kinetic parameters of alprazolam, caffeine, paraxanthine, tolbutamide, 4-
hydroxytolbutamide and digoxin were observed. 
CYP1A2 appears to be induced by Hypericum extract only in females, the activities of 
CYP2D6, NAT2, and XO were not affected by Hypericum extract (Wenk et al 2004). 
The causality of some of the published interactions is questioned by Schulz (2005), 
particularly the combinations with serotonin reuptake inhibitors and digoxin.  
The elevated activity of CYP3A returns to basal level approximately 1 week after termination 
of Hypericum administration (Imai et al 2008). Therefore the warning in the monograph is 
justified that Hypericum administration should be discontinued at least 10 days prior to 
elective surgery. 
 
I.3.3.5.3 Use in pregnancy and lactation 
Five mothers who were taking 300 mg of St. John's wort 3 times daily (LI 160 [Jarsin]) and 
their breastfed infants were assessed by Klier at al (2006). Thirty-six breast milk samples 
(foremilk and hindmilk collected during an 18-hour period) and 5 mothers' and 2 infants' 
plasma samples were analyzed for hyperforin levels. Hyperforin is excreted into breast milk at 
low levels. However, the compound was at the limit of quantification in the 2 infants' plasma 
samples (0.1 ng/mL). Milk/plasma ratios ranged from 0.04 to 0.13. The relative infant doses 
of 0.9% to 2.5% indicate that infant exposure to hyperforin through milk is comparable to 
levels reported in most studies assessing anti-depressants or neuroleptics. No side effects were 
seen in the mothers or infants. The authors conclude that these results add to the evidence of 
the relative safety of St. John's wort while breast-feeding found in previous observational 
studies.  
 
In a review Dugoua et al (2006) searched 7 electronic databases and compiled data according 
to the grade of evidence found. The authors found very weak scientific evidence based on a 
case report that St Johns wort is of minimal risk when taken during pregnancy. There is in 
vitro evidence from animal studies that St John's wort during pregnancy does not affect 
cognitive development nor cause long-term behavioral defects, but may lower offspring birth 
weight. There is weak scientific evidence that St. John's wort use during lactation does not 
affect maternal milk production nor affect infant weight, but, in a few cases, may cause colic, 
drowsiness or lethargy. There is weak scientific evidence that St John's wort induces CYP450 
enzymes, which may lower serum medication levels below therapeutic range; this may be of 
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concern when administering medications during pregnancy and lactation. Caution is 
warranted with the use of St John's wort during pregnancy until further high quality human 
research is conducted to determine its safety. St John's wort use during lactation appears to be 
of minimal risk, but may cause side effects. Caution is warranted when using medications 
along with St John's wort.   
 
I.3.3.5.4 Overdose 
Karalapillai & Bellomo (2007) reported a case of overdose in suicidal intention of a 16-year-
old girl. It has been reported that the girl had taken up to 15 tablets per day for 2 weeks and 50 
tablets just before hospitalisation. Seizures and confusion were diagnosed, after 6 days the 
EEG was normal, no further seizures occurred in the following 6 months. The published data 
on the composition of the tablets are not clear (‘300 µg tablets’). 
 
Assessor’s comment: 
In a pesonal communication the author confirmed that there is a typing error in the 
publication. The product contained 300 mg extract per tablet. These symptoms occurred 
therefore after ingestion of 4500 mg extract per day over a period of 2 weeks (approximately 
the 5-fold therapeutic dose) and an additional dose of 15000 mg extract (approximately the 
17-fold therapeutic dose).  
 
I.3.3.5.5 Drug abuse 
 
I.3.3.5.6 Withdrawal and rebound 
Beckman et al (2000) conducted a telephone survey of 43 subjects who had taken Hypericum 
extract to assess demographics, psychiatric and medical conditions, dosage, duration of use, 
reason for use, side effects, concomitant drugs, professional consultation, effectiveness, 
relapse, and withdrawal effects. Most subjects reported taking Hypericum extract for 
depression, and 74% did not seek medical advice. Mean dosage was 475.6+/-360 mg/day 
(range 300-1200 mg/day) and mean duration of therapy was 7.3+/-10.1 weeks (range 1 day-5 
yrs). Among 36 (84%) reporting improvement, 18 (50%) had a psychiatric diagnosis. Twenty 
(47%) reported side effects, resulting in discontinuation in five (12%) and one emergency 
room visit. Two consumers experienced symptoms of serotonin syndrome and three reported 
food-drug interactions. Thirteen consumers experienced withdrawal symptoms and two had a 
depressive relapse. These data suggest the need for greater consumer and provider awareness 
of the potential risks of Hypericum extract in self-care of depression and related syndromes. 
 
Assessor’s comment: 
Details on the type of products used are missing. Data from a telephone survey should be 
assessed reluctantly. 
 
I.3.3.5.7 Effects on ability to drive or operate machinery or impairment of mental ability 
I.3.3.6 Assessor’s overall conclusions on clinical safety 
The adverse events observed in clinical trials, which are most probably linked to the study 
medication are in general mild, the frequency is, compared to synthetic antidepressants 
considerably lower. The induction of CYP3A4 is well documented; the amount is directly 
correlated with the content of hyperforin in the herbal preparation. Pharmacokinetic 
interactions are documented for several drug substances metabolised via CYP3A4 having 
with a narrow therapeutic range. Hypericum extracts should not be used concomitantly with 
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these substances. Adequate studies with extracts with low hyperforin content which could 
justify exemptions in the wording of contraindications, special warnings and in the 
interactions section of the monograph are missing. Nevertheless, the risk / benefit assessment 
favours the benefits of the hypericum dry extracts. 
The induction of the CYP3A4 is reversible within approximately 10 days after stopping 
ingestion of Hypericum extracts. Therefore the administration should be discontinued at least 
10 days prior to surgery. 
The only risk of the cutaneous application of hypericum oil seems to be the phototoxicity 
when treated skin is exposed to intense sunlight. A special warning should inform the patient. 
 
 
I.4 ASSESSOR’S OVERALL CONCLUSIONS 
Dry extracts of Hypericum perforatum demonstrated in several controlled clinical trials 
superiority over placebo and non inferiority against standard medication in mild to moderate 
major depression. Therefore these types of extracts are proposed for ‘well-established use’. 
The herbal tea and other mostly liquid extracts orally applied have a long tradition in folk 
medicine for the treatment of low mood, anxiety, to ‘strenghten the nerves’. Provided that the 
duration of use is restricted to several days the traditional use of such herbal preparations can 
be granted. The cutaneous application of oil preparations is plausible based on 
pharmacological tests. 
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II COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., 
HERBA 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
To be specified for the individual finished product. 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION5 6 
 
Well-established use  
 
With regard to the marketing authorisation 
application of Article 10(a) of Directive 
2001/83/EC as amended 
 
Hypericum perforatum L., herba  
(St. John’s Wort) 
 
i) Herbal substance 
Not applicable 
 
ii) Herbal preparations  
A) Dry extract (DER 3-6:1), extraction 
solvent methanol (80% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
B) Dry extract (DER 4-7:1), extraction 
solvent methanol (80% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
C) Dry extract (DER 3-6:1), extraction 
solvent ethanol (80% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
D) Dry extract (DER 5-7:1), extraction 
solvent ethanol (60% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
E) Dry extract (DER 5-7:1), extraction 
solvent ethanol (60% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
Traditional use  
 
With regard to the registration application of 
Article 16d(1) of Directive 2001/83/EC as 
amended 
 
Hypericum perforatum L., herba  
(St. John’s Wort) 
 
i) Herbal substance 
Whole or cut, dried flowering tops, 
harvested during flowering time. 
 
ii) Herbal preparations7 
A) Dry extract (DER 4-7:1), extraction 
solvent ethanol 38% (v/v) 
B) Dry extract (DER 3.5-6:1), extraction 
solvent ethanol 60% (m/m) 
C) Dry extract (DER 5-7:1), extraction 
solvent ethanol 70% (m/m) 
D) Liquid extract (DER 1:4-20), extraction 
solvent vegetable oil8 
E) Liquid extract (DER 1: 13), extraction 
solvent maize oil 
F) Tincture (DER 1:10), extraction solvent 
ethanol 45-50% (v/v) 
G) Tincture (DER 1:5), extraction solvent 
ethanol 50% (v/v) 
H) Liquid extract (DER 1:2), extraction 
solvent ethanol 50% 
I) Liquid extract (DER 1: 5-7), extraction 
solvent ethanol 50%. 
J) Expressed juice from the fresh herb 
                                                 
5 The material complies with the Pharm. Eur. monograph (ref. 01/2008:1438) 
6 The declaraction of the active substance(s) for an individual finished product should be in accordance with the relevant 
herbal quality guidance. 
7 For safety reasons, the amount of hyperforin and hypericin should be specified. 
8 Preparation: maceration of the fresh or dried herbal substance with vegetable oil over a period of 2 days to 
several weeks under sun light exposure. 
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F) Dry extract (DER 2.5-5:1), extraction 
solvent ethanol (60% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
G) Dry extract (DER 5-8:1), extraction 
solvent ethanol (50% v/v), hypericin 
0.10-0.30%, hyperforin > 2%, 
flavonoids > 6.0% 
 
(DER 1.25-2.5:1) 9 
K) Comminuted herbal substance 
 
 
3. PHARMACEUTICAL FORM 
 
Well-established use  
Herbal preparation in solid dosage forms for 
oral use. 
The pharmaceutical form should be described 
by the European Pharmacopoeia full standard 
term. 
Traditional use  
Comminuted herbal substance for tea 
preparation. 
Herbal preparations A, B, C, E, F, G, H, I, J, 
K in liquid or solid dosage forms for oral use. 
Herbal preparations D, F, G, K in liquid or 
semi solid dosage forms for cutaneous use. 
 
The pharmaceutical form should be described 
by the European Pharmacopoeia full standard 
term. 
 
 
4. CLINICAL PARTICULARS 
 
4.1. Therapeutic indications 
 
Well-established use  
 
Herbal medicinal product for the treatment of 
mild to moderate depressive episodes. 
 
 
Traditional use  
 
Indication 1: 
Herbal substance, herbal preparations A, B, 
C, E, F, G, H, I, J, K: 
Traditional herbal medicinal product for the 
symptomatic relief of temporary neurasthenia 
(e.g. difficulty in concentrating, inefficient 
thinking, feeling of physical weakness and 
exhaustion after minimal effort, 
gastrointestinal discomfort). 
 
 
Indication 2: 
Herbal preparations D, F, G, K: 
Traditional herbal medicinal product for the 
symptomatic treatment of minor 
inflammations of the skin (such as sunburn) 
and as an aid in healing of minor wounds. 
                                                                                                                                                        
9 Fresh material complies with the Pharm. Eur. monograph (ref. 01/2008:1438) when dried. 
- 80 - 
 
The product is a traditional herbal medicinal 
product for use in specified indication(s) 
exclusively based upon long-standing use. 
 
4.2. Posology and method of administration 
 
Well-established use  
 
Posology 
 
Adults and elderly: 
Herbal preparation A: 
Single dose: 300 mg 
Dosage frequency: 3 times daily 
Daily dose: 900 mg 
 
 
Herbal preparation B: 
Single dose: 300-600 mg 
Dosage frequency: 1-3 times daily 
Daily dose: 600-1800 mg 
 
 
Herbal preparation C: 
Single dose: 900 mg 
Dosage frequency: 1 single daily dose 
Daily dose: 900 mg 
 
 
Herbal preparation D: 
Single dose: 350 mg 
Dosage frequency: 3 times daily 
Daily dose: 1050 mg 
 
 
Herbal preparation E: 
Single dose: 400 mg 
Dosage frequency: 2 times daily  
Daily dose: 800 mg 
 
Herbal preparation F: 
Single dose: 300-600 mg 
Dosage frequency: 2-3 times daily 
Daily dose: 900-1200 mg 
 
 
Herbal preparation G: 
Single dose: 612 mg 
Dosage frequency: 1 single daily dose 
Daily dose: 612 mg 
Traditional use  
 
Posology 
 
Indication 1: 
 
Adults, elderly: 
 
Herbal preparation A: 
 Single dose: 60-180 mg 
 Daily dose: 180-360 mg 
 
Herbal preparation B: 
Single dose: 85-300 mg 
Daily dose: 510 – 600 mg 
 
Herbal preparation C: 
Single dose: 270 mg 
Daily dose: 540 mg 
 
Herbal preparation E: 
Single dose: 200 mg 
Daily dose: 600 mg 
 
Herbal preparation F: 
 Single dose: 2-4 ml 
 Daily dose: 6-12 ml 
 
Herbal preparation G: 
 Single dose: 1-1.5 ml 
 Daily dose: 3-4.5 ml 
 
Herbal preparation H: 
 Single dose: 0.8-1.2 ml 
 Daily dose: 2.4-3.6 ml 
 
Herbal preparation I: 
 Single dose: 1.3 ml 
 Daily dose: 4.0 ml 
 
Herbal preparation J: 
Single dose: 10-20 ml 
Daily dose: 10-20 ml 
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Children and adolescents: 
The use in children and adolescents under 18 
years of age is not recommended (see section 
4.4 ‘Special warnings and precautions for 
use’). 
 
Duration of use 
The onset of the effect can be expected within 
4 weeks of treatment. If the symptoms persist 
during the use of the medicinal product, a 
doctor should be consulted. 
 
Method of administration 
 
Oral use  
 
 
Herbal preparation K: 
For tea preparation: 
Single dose: 2 g 
Daily dose: 4 g 
 
In solid dosage forms: 
Single dose: 300-500 mg 
Daily dose: 900-1000 mg 
 
Children, adolescents: 
The use in children and adolescents under 18 
years of age is not recommended (see section 
4.4 ‘Special warnings and precautions for 
use’). 
 
Indication 2: 
 
Adolescents, adults, elderly: 
Herbal preparations D, K: 
Cutaneous administration of the undiluted 
herbal preparation 
 
Herbal preparations F, G: 
Cutaneous administration of the undiluted or 
diluted herbal preparation 
 
Children: 
The use in children and adolescents under 18 
years of age is not recommended (see section 
4.4 ‘Special warnings and precautions for 
use’). 
 
Duration of use 
 
Indication 1: 
 
2 weeks 
If the symptoms persist longer than 2 weeks 
during the use of the medicinal product, a 
doctor or a qualified health care practitioner 
should be consulted. 
 
Indication 2: 
 
1 week 
If the symptoms persist longer than 1 week 
during the use of the medicinal product, a 
doctor or a qualified health care practitioner 
should be consulted. 
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Method of administration 
 
Indication 1: 
 
Oral use  
 
Indication 2: 
 
Cutaneous use 
 
 
4.3. Contraindications 
 
Well-established use  
 
Hypersensitivity to the active substance. 
 
Hypericum dry extract must not be used 
concomitantly with cyclosporine, tacrolimus, 
digoxin, amprenavir, indinavir and other 
protease-inhibitors, irinotecan and other 
cytostatic agents. 
 
Traditional use  
 
Indication 1: 
 
Hypersensitivity to the active substance. 
 
Hypericum extracts must not be used 
concomitantly with cyclosporine, tacrolimus, 
digoxin, amprenavir, indinavir and other 
protease-inhibitors, irinotecan and other 
cytostatic agents. 
 
Indication 2: 
 
Hypersensitivity to the active substance. 
 
4.4. Special warnings and precautions for use 
 
Well-established use  
 
When coadministered with anticoagulants 
from the coumarin-type the serum 
concentration of these substances should be 
controlled regularly. 
During the treatment intense UV-exposure 
should be avoided. 
 
The product should be discontinued at least 
10 days prior to elective surgery due to the 
potential for interactions with medicinal 
products used during general and regional 
anaesthesia. 
 
Since no sufficient data on the safe use in 
children are available the use in children and 
adolescents under 18 years of age is not 
recommended. 
 
Traditional use  
 
Indication 1: 
 
When coadministered with anticoagulants 
from the coumarin-type the serum 
concentration of these substances should be 
controlled regularly. 
During the treatment intense UV-exposure 
should be avoided. 
 
The product should be discontinued at least 
10 days prior to elective surgery due to the 
potential for interactions with medicinal 
products used during general and regional 
anaesthesia. 
 
Since no data on the safe use in children are 
available the use in children and adolescents 
under 18 years of age is not recommended. 
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For tinctures the appropriate labelling for 
ethanol, taken from the ‘Guideline on 
excipients in the label and package leaflet of 
medicinal products for human use’, must be 
included. 
 
Indication 2: 
 
During the treatment intense UV-exposure of 
the respective skin areas should be avoided. 
 
Since no data on the safe use in children are 
available the use in children and adolescents 
under 18 years of age is not recommended. 
 
If signs of skin infections are observed, a 
doctor or a qualified healthcare practitioner 
should be consulted. 
 
4.5. Interactions with other medicinal products and other forms of interaction 
 
Well-established use  
 
Contraindicated is the concomitant use of 
cyclosporine, tacrolimus, digoxin, 
amprenavir, indinavir and other protease-
inhibitors, irinotecan and other cytostatic 
agents. 
 
Special care should be taken with alprazolam, 
amitriptyline, fexofenadine, benzodiazepines, 
methadone, simvastatin, theophyline, 
midazolam, triptans and warfarin, because a 
reduction of plasma concentrations is 
possible.  
 
The reduction of plasma concentrations of 
oral contraceptives may lead to bleeding and 
unwanted pregnancies. 
 
Hypericum dry extract may cause a 
serotonergic syndrome when combined with 
antidepressants such as serotonine reuptake 
inhibitors (e.g. sertraline, paroxetine, 
nefazodone) or with buspirone.  
Traditional use  
 
Indication 1: 
 
Contraindicated is the concomitant use of 
cyclosporine, tacrolimus, digoxin, 
amprenavir, indinavir and other protease-
inhibitors, irinotecan and other cytostatic 
agents. 
 
Special care should be taken with alprazolam, 
amitriptyline, fexofenadine, benzodiazepines, 
methadone, simvastatin, theophyline, 
midazolam, triptans and warfarin, because a 
reduction of plasma concentrations is 
possible.  
 
The reduction of plasma concentrations of 
oral contraceptives may lead to bleeding and 
unwanted pregnancies. 
 
Hypericum dry extract may cause a 
serotonergic syndrome when combined with 
antidepressants such as serotonine reuptake 
inhibitors (e.g. sertraline, paroxetine, 
nefazodone) or with buspirone. 
 
Patients taking other medicines on 
prescription should consult a doctor or 
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pharmacist before taking Hypericum. 
Indication 2: 
 
None reported 
 
4.6. Pregnancy and lactation 
 
Well-established use  
 
In the absence of sufficient data, the use 
during pregnancy and lactation is not 
recommended. 
Traditional use  
 
In the absence of sufficient data, the use 
during pregnancy and lactation is not 
recommended. 
 
4.7. Effects on ability to drive and use machines 
 
Well-established use  
 
No studies on the effect on the ability to drive 
and use machines have been performed. 
Traditional use  
 
No studies on the effect on the ability to drive 
and use machines have been performed. 
 
4.8. Undesirable effects 
 
Well-established use  
 
Gastrointestinal disorders, allergic reactions 
of the skin, fatigue and restlessness may 
occur. The frequency is not known. 
 
Fair-skinned individuals may react with 
intensified sunburn-like symptoms under 
intense sunlight. 
 
If other adverse reactions not mentioned 
above occur, a doctor or a pharmacist should 
be consulted. 
Traditional use  
 
Indication 1: 
 
Gastrointestinal disorders, allergic reactions 
of the skin, fatigue and restlessness may 
occur. The frequency is not known. 
 
Fair-skinned individuals may react with 
intensified sunburn-like symptoms under 
intense sunlight. 
 
If other adverse reactions not mentioned 
above occur, a doctor or a qualified health 
care practitioner should be consulted. 
 
Indication 2: 
 
Skin reactions may occur. The frequency is 
not known 
 
If other adverse reactions not mentioned 
above occur, a doctor or a qualified health 
care practitioner should be consulted. 
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4.9. Overdose 
 
Well-established use  
 
After ingestion of overdoses the patient 
should be protected from sunlight and other 
UV-sources for 1-2 weeks. 
Traditional use  
 
Indications 1, 2: 
 
No case of overdose has been reported. 
 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1. Pharmacodynamic properties 
 
Well-established use  
 
Pharmacotherapeutic group:  
Other antidepressants 
ATC code: N06AX 
 
Hypericum dry extract inhibits the 
synaptosomal uptake of the neurotransmitters 
noradrenaline and serotonine. Subchronic 
treatment causes a down-regulation of beta-
adrenoreceptors; it changes the behaviour of 
animals in several antidepressant models 
(e.g., forced swimming test) similar to other 
antidepressants. Napthodianthrones 
(e.g. hypericin, pseudohypericin), 
phloroglucin derivatives (e.g. hyperforin) and 
flavonoids contribute to the activity. 
Traditional use  
 
Not required as per Article 16c(1)(a)(iii) of 
Directive 2001/83/EC as amended. 
 
5.2. Pharmacokinetic properties 
 
Well-established use  
 
The absorption of hypericin is delayed and 
starts about 2 hours after administration. The 
half-life of hypericin is about 37 hours. 
Maximum hyperforin levels are reached 
about  
3 hours after administration; no accumulation 
could be detected. Hyperforin and the 
flavonoid miquelianin can cross the blood-
brain-barrier. 
 
Traditional use  
 
Not required as per Article 16c(1)(a)(iii) of 
Directive 2001/83/EC as amended. 
 
Hyperforin is a strong enzyme inducer and 
may interact with many medicinal products. 
Therefore, for traditional herbal medicines, 
the hyperforin content should be kept at a 
minimum. 
 
5.3. Preclinical safety data 
 
Well-established use  
 
Studies on acute toxicity and repeated dose 
Traditional use  
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toxicity did not show signs of toxic effects.  
The weak positive results of an ethanolic 
extract in the AMES-test (Salmonella 
typhimurium TA 98 and TA 100, with and 
without metabolic activation) could be 
assigned to quercetin. No signs of 
mutagenicity could be detected in further in 
vitro and in vivo test systems. 
No adequate tests on reproduction toxicity 
have been performed. 
 
Tests on the carcinogenic potential have not 
been performed. 
 
Phototoxicity: 
After oral application of dosages of 1800 mg 
of an extract per day for 15 days the skin 
sensitivy against UVA was increased, and the 
minimum dose for pigmentation was 
significantly reduced. In the recommended 
dosage no signs of phototoxicity are reported. 
Studies on acute toxicity and repeated dose 
toxicity did not show signs of toxic effects.  
The weak positive results of an ethanolic 
extract in the AMES-test (Salmonella 
typhimurium TA 98 and TA 100, with and 
without metabolic activation) could be 
assigned to quercetin. No signs of 
mutagenicity could be detected in further in 
vitro and in vivo test systems. 
No adequate tests on reproduction toxicity 
have been performed. 
 
Tests on the carcinogenic potential have not 
been performed. 
 
Phototoxicity: 
After oral application of dosages of 1800 mg 
of an extract per day for 15 days the skin 
sensitivy against UVA was increased, and the 
minimum dose for pigmentation was 
significantly reduced. In the recommended 
dosage no signs of phototoxicity are reported. 
 
 
6. PHARMACEUTICAL PARTICULARS 
 
Well-established use  
 
Extracts should be quantified with respect to 
hypericin, hyperforin and flavonoids10. 
Traditional use  
 
Not applicable. 
 
 
7. DATE OF COMPILATION/LAST REVISION 
 
August 2008 
 
 
 
 
                                                 
10 Pharm. Eur. monograph (ref. 01/2008:0765) Extracts. 
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Discussion 
 
Hypericum perforatum L. is an old medicinal herb with a long history of traditional use. In the 
Austrian folk medicine Hypericum is the most important medicinal plant. Numerous 
indications can be found in the literature, such as wound healing, gout, rheumatism for 
external use and dyspeptic complaints and ‘to strengthen the nerves’ for internal use.  
The literature search and the evaluation of the scientific knowledge for the preparation of an 
assessment report and a community monograph for the European Medicines Agency EMEA 
were performed under several aspects:  
 
Each indication has strictly to be connected with a well defined herbal preparation and a 
defined posology. As a consequence scientific literature data bases were searched for clinical 
data, recent and historical pharmaceutical literature was evaluated with respect to traditional 
indications and preparations. Additional data on authorized products were collected in the EU 
member states. 
 
Several liquid extracts, three dry extracts, the expressed juice from the fresh herb and the 
herbal tea were found to be traditional preparations. Out of the nearly endless lists of 
traditional indications only neurasthenia for oral use and symptomatic treatment of minor 
inflammations of the skin were found to be plausible. The posology for all of these 
preparations can be found in the literature. Although hypericum oil is traditionally used also 
in children, the use should be limited to persons older than 18 years since no sufficient data on 
the safe use in the paediatric population could be found. The oral use of hypericum oil was 
not supported, there are no constituents known which would make this use plausible. 
 
Seven dry extracts were found to fulfil the criteria for well-established use, which means at 
least one well conducted clinical trial and at least 10 years of broad medicinal use. A further 
dry extract with sufficient clinical evidence could not be included into the draft monograph: 
the extract ZE117 is a refined extract, the amount of hyperforin is reduced. Since details of 
the manufacturing process were not available this extract could not be considered in the 
monograph.  
All of these extracts were clinically tested in patients with single mild to moderate depressive 
episodes and recurrent mild to moderate depressive episodes. The minimal daily dose is about 
600 mg extract. The results of clinical trials where the equivalence with standard medication 
was examined the fact that synthetic antidepressants usually lead to xerostomia should be 
considered. Blinding is therefore not really possible.  
The constituents of the extracts which could be responsible for the antidepressant activity are 
still under discussion. Extracts with predominately positive outcome (superiority against 
placebo, equivalence to reference medication) meet the definition of the monograph of the 
Pharm. Eur. (Extraction solvent: Ethanol 50-80 % or methanol 50-80 %; Hypericin: 0.10-0.30 
%, Hyperforin: < 6,0 %, Flavonoids: 6,0 %).  
Most authors suggest that hyperforin is mainly responsible for the antidepressant activity. 
Since the extract ZE117 with low content of hyperforin exhibited antidepressant activity in 
several clinical trials other constituents should be considered too. In a recent publication the 
possible role of the flavonoids is discussed. Unfortunately the content of flavonoids is not 
declared in most cases. 
Hypericum gained interest in clinical pharmacology at least since pharmacokinetic 
interactions with other substances became evident. Hyperforin is able to induce CYP 3A, 
therefore numerous warnings and contraindications are included into the draft monograph. 
The clinical trials with the extract ZE117 were too short. Therefore it is not allowed to 
conclude that extracts with a low hyperforin content can be used without such restrictions. 
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A lot of more clinical and not clinical trials about further different effects were published. 
Some of these studies confirm the above mentioned traditional indications (for example: The 
wound healing effect activity of Hypericum perforatum (Ozturk et al 2006)), other indications 
like “support in smoking cessation” or “treatment of alcoholism” might be in context with the 
antidepressant activity. These activities and indications demonstrate the potency of hypericum 
extracts, but further data is necessary to confirm these. 
 
A further interesting point is the phototoxicity of Hypericum perforatum L. From traditional 
use of hypericum oil it is known, that the expose of sunlight to the treated parts of the skin 
could cause skin irritations. Therefore it is recommended to protect treated skin from sunlight. 
However, orally administrated hypericum dry extract under therapeutically dose is safe in this 
respect; no significant increase of photosensitivity was observed (Schempp 2003 and 2006).  
 
Only poor clinical data are available on the use of Hypericum in children as well as during 
pregnancy and lactation. Therefore the use in this population is not recommended.  
Surprisingly the published preclinical safety data are not comprehensive. 
 
The here presented review and assessment reveals that Hypericum perforatum is still a 
valuable herbal substance. Dry extracts can be recommended for the treatment of mild to 
moderate depressive episodes. Liquid extracts and other preparations are traditionally used 
orally in neurasthenia, topically for the treatment of small wounds or minor inflammations of 
the skin. The preparations can be used safely provided that the possible pharmacokinetic 
interactions are considered during therapy. 
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Abstract 
 
The aim of this work was to draw up a first draft of an assessment report of Hypericum 
perforatum L. to evaluate the traditional and the well-established use of preparations of 
hyperici herba.  
 
Literature was searched in PubMed, the library of pharmacy of the University of Vienna, the 
library of the Medical University of Vienna and in the AGES PharmMed (Austrian Medicines 
Agency) from March 2007 to June 2008. The assessment of the literature was performed 
considering the guidelines of the EMEA (European Medicines Agency). 
 
The data presented in this draft monograph represent the most recent and comprehensive 
review of the well-established and traditional use of Hypericum perforatum in the European 
Union. 
 
Seven different dry extracts of Hyperici herba were found to fulfil the criteria of well-
established use including clinical evidence of efficacy and broad therapeutic use for more than 
10 years. The indication ‘mild to moderate depressive episodes’ is proposed for products 
containing one of these extracts. 
 
Liquid preparations and some other dry extracts are proposed for traditional use in the 
indication ‘Neurasthenia’. All these extracts are more than 30 years in medicinal use in the 
European Union. The topical use of liquid extracts (including hypericum oil) is proposed in 
the traditional indication ‘treatment of small wounds and minor inflammations of the skin’. 
 
Additionally this present assessment of the literature comprises also aspects like 
pharmacology, pharmacokinetics, preclinical safety data, use in special populations, side 
effects and interactions. 
 
Hypericum perforatum L. is an effective medicinal herb in the above mentioned indications. 
Particularly in the therapy of depression the effects which can be achieved are equal to 
reference medication. One main advantage of hypericum is the low rate of undesirable effects 
and the good compliance. In future it could be possible that the above mentioned indications 
will be extended, for example depression combined with alcoholism or the therapy of the 
premenstrual syndrome. 
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Zusammenfassung 
 
Das Ziel meiner Arbeit war die Erstellung eines Vorschlags eines Berichts über Hypericum 
perforatum L., um die traditonelle Anwendung und die Anwendung nach well-established use 
von Johanniskrautpräparaten zu evaluieren. 
 
Aus diesem Grund suchte ich nach Literatur in der Pharmaziebibliothek der Universität Wien, 
in der Bibliothek der Medizin Universität Wien und bei der AGES PharmMed (Austrian 
Medicines Agency) vom März 2007 bis Juni 2008. Der Bericht wurde nach den Richtlinien 
der EMEA (European Medicines Agency) erstellt. 
 
Die dargestellten Daten dieses Berichts sind die aktuellsten und umfangsreichsten, die über 
die traditionelle Anwendung und die Anwendung nach well-established use von 
Johanniskrautpräparaten in der Europäischen Union dargestellt wurden. 
 
Sieben verschiedene Trockenextrakte von Hyperici herba wurden gefunden, die die Kriterien 
der Anwendung nach well-established use erfüllen, inklusive klinischer Daten über die 
Wirksamkeit und die weitreichende therapeutischer Anwendung für mehr als 10 Jahre. Die 
Indikation ‘mild to moderate depressive episodes’ ist vorgeschlagen für Präparate, die eines 
dieser Extrakte enthalten. 
 
Flüssige Zubereitungen und einige Trockenextrakte sind indiziert zur traditionellen 
Anwendung bei der Indikation „Neurasthenia“. Alle diese Extrakte sind für mehr als 30 Jahre 
in therapeutischer Anwendung in der Europäischen Union. Für die traditionellen topische 
Indikation ‘treatment of small wounds and minor inflammations of the skin’ werden flüssige 
Extrakte (inklusive Johanniskrautöl) angewendet. 
 
Außerdem berücksichtigt der erstellte Bericht Punkte wie Pharmakologie, Pharmakokinetik, 
Präklinische Sicherheitsdaten, die Anwendung für spezielle Bevölkerungsgruppen, 
Nebenwirkungen und Interaktionen. 
 
Hypericum perforatum L. ist eine sehr wichtige Arzneipflanze bei der Behandlung der 
erwähnten Indikationen, besonderes wichtig ist die Anwendung bei Depressionen, wo sie 
gleich wirksam ist wie die Vergleichmedikation. Ihr großer Vorteil ist die geringe Rate 
unerwünschter Wirkungen und eine gute Compliance. In Zukunft ist es mögliche, dass die 
Indikationen von Johanniskraut erweitert werden, wie z.B. zur Therapie von Depressionen in 
Zusammenhang mit Alkoholismus oder zur Therapie des Premenstrualen Syndrom. 
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